473 results on '"Rath, GK"'
Search Results
2. Can Field-in-field Technique Replace Wedge Filter in Radiotherapy Treatment Planning: A Comparative Analysis in Various Treatment Sites
- Author
-
Prabhakar, R, Julka, PK, and Rath, GK
- Published
- 2008
3. A Study on Contralateral Breast Surface Dose for Various Tangential Field Techniques and the Impact of Set-up Error on This Dose
- Author
-
Prabhakar, R, Haresh, KP, Julka, PK, Ganesh, T, Rath, GK, Joshi, RC, Sasindran, M, Naik, KK, and Sridhar, PS
- Published
- 2007
4. Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia
- Author
-
Goel, Harsh, Rahul, Ekta, Gupta, Ishan, Chopra, Anita, Ranjan, Amar, Gupta, Aditya Kumar, Meena, Jagdish Prasad, Viswanathan, Ganesh Kumar, Bakhshi, Sameer, Misra, Aroonima, Hussain, Showket, Kumar, Ritesh, Singh, Archana, Rath, GK, Sharma, Ashok, Mittan, Sandeep, and Tanwar, Pranay
- Subjects
hemic and lymphatic diseases ,Review Article ,neoplasms - Abstract
Acute myeloid leukemia (AML) is a complex, aggressive myeloid neoplasm characterized by frequent somatic mutations that influence different functional categories' genes, resulting in maturational arrest and clonal expansion. AML can arise de novo (dn-AML) or can be secondary AML (s-AML) refers to a leukemic process which may arise from an antecedent hematologic disorder (AHD-AML), mostly from a myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) or can be the result of an antecedent cytotoxic chemotherapy or radiation therapy (therapy-related AML, t-AML). Clinical and biological features in secondary and therapy-related AML are distinct from de novo AML. Secondary and therapy-related AML occurs mainly in the elderly population and responds worse to therapy with higher relapse rates due to resistance to cytotoxic chemotherapy. Over the last decade, advances in molecular genetics have disclosed the sub-clonal architecture of secondary and therapy-related AML. Recent investigations have revealed that cytogenetic abnormalities and underlying genetic aberrations (mutations) are likely to be significant factors dictating prognosis and critical impacts on treatment outcome. Secondary and therapy-related AML have a poorer outcome with adverse cytogenetic abnormalities and higher recurrences of unfavorable mutations compared to de novo AML. In this review, we present an overview of the clinical features of secondary and therapy-related AML and address the function of genetic mutations implicated in the pathogenesis of secondary leukemia. Detailed knowledge of the pathogenetic mechanisms gives an overview of new prognostic markers, including targetable mutations that will presumably lead to the designing and developing novel molecular targeted therapies for secondary and therapy-related AML. Despite significant advances in knowing the genetic aspect of secondary and therapy-related AML, its influence on the disease's pathophysiology, standard treatment prospects have not significantly evolved during the past three decades. Thus, we conclude this review by summarizing the modern and developing treatment strategies in secondary and therapy-related acute myeloid leukemia.
- Published
- 2021
5. Current Trends in Management of Oral Mucositis in Cancer Treatment
- Author
-
Shankar, Abhishek, Roy, Shubham, Bhandari, Menal, Rath, GK, Biswas, Aalekhya Sharma, Kanodia, Ravi, Adhikari, Narayan, and Sachan, Rashika
- Subjects
treatment ,Oral Mucositis ,cancer ,Review - Abstract
Oral Mucositis (OM) is among the most common and dreaded toxicities of cancer therapy. It occurs in almost all patients who receive radiation therapy in which areas of oral and oropharyngeal mucosa are included in the treatment field. With the advent of chemotherapy in 1940 and its extended clinical legacy, it is only within the past two decade or so that mucositis’ complex pathobiology has become fully appreciated. There are still many unanswered questions about the risk factors for developing OM, but historically, risk factors have been attributed to both therapy and patient m characteristics. One thing that has been consistent from the initial descriptions of its clinical manifestations has been the frustration on the part of clinicians and patients with the scarcity of therapeutic options to prevent or treat the condition, or effectively ameliorate the symptoms. Clinicians, researchers and those involved in oral and periodontal medicine should join hand in hand in persuit of understanding and developing treatment strategies for treatment of inflammatory conditions like OM in oncology. This will lead to development of effective treatments and reducing the burden of OM and other inflammatory conditions in oncology.
- Published
- 2017
6. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study
- Author
-
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I, Abdulle ASM, Abebe ND, Abraha HN, Abu-Raddad LJ, Abualhasan A, Adedeji IA, Advani SM, Afarideh M, Afshari M, Aghaali M, Agius D, Agrawal S, Ahmadi A, Ahmadian E, Ahmadpour E, Ahmed MB, Akbari ME, Akinyemiju T, Al-Aly Z, AlAbdulKader AM, Alahdab F, Alam T, Alamene GM, Alemnew BTT, Alene KA, Alinia C, Alipour V, Aljunid SM, Bakeshei FA, Almadi MAH, Almasi-Hashiani A, Alsharif U, Alsowaidi S, Alvis-Guzman N, Amini E, Amini S, Amoako YA, Anbari Z, Anber NH, Andrei CL, Anjomshoa M, Ansari F, Ansariadi A, Appiah SCY, Arab-Zozani M, Arabloo J, Arefi Z, Aremu O, Areri HA, Artaman A, Asayesh H, Asfaw ET, Ashagre AF, Assadi R, Ataeinia B, Atalay HT, Ataro Z, Atique S, Ausloos M, Avila-Burgos L, Avokpaho EFGA, Awasthi A, Awoke N, Ayala Quintanilla BP, Ayanore MA, Ayele HT, Babaee E, Bacha U, Badawi A, Bagherzadeh M, Bagli E, Balakrishnan S, Balouchi A, Bärnighausen TW, Battista RJ, Behzadifar M, Bekele BB, Belay YB, Belayneh YM, Berfield KKS, Berhane A, Bernabe E, Beuran M, Bhakta N, Bhattacharyya K, Biadgo B, Bijani A, Bin Sayeed MS, Birungi C, Bisignano C, Bitew H, Bjørge T, Bleyer A, Bogale KA, Bojia HA, Borzì AM, Bosetti C, Bou-Orm IR, Brenner H, Brewer JD, Briko AN, Briko NI, Bustamante-Teixeira MT, Butt ZA, Carreras G, Carrero JJ, Carvalho F, Castro C, Castro F, Catalá-López F, Cerin E, Chaiah Y, Chanie WF, Chattu VK, Chaturvedi P, Chauhan NS, Chehrazi M, Chiang PP, Chichiabellu TY, Chido-Amajuoyi OG, Chimed-Ochir O, Choi JJ, Christopher DJ, Chu DT, Constantin MM, Costa VM, Crocetti E, Crowe CS, Curado MP, Dahlawi SMA, Damiani G, Darwish AH, Daryani A, das Neves J, Demeke FM, Demis AB, Demissie BW, Demoz GT, Denova-Gutiérrez E, Derakhshani A, Deribe KS, Desai R, Desalegn BB, Desta M, Dey S, Dharmaratne SD, Dhimal M, Diaz D, Dinberu MTT, Djalalinia S, Doku DT, Drake TM, Dubey M, Dubljanin E, Duken EE, Ebrahimi H, Effiong A, Eftekhari A, El Sayed I, Zaki MES, El-Jaafary SI, El-Khatib Z, Elemineh DA, Elkout H, Ellenbogen RG, Elsharkawy A, Emamian MH, Endalew DA, Endries AY, Eshrati B, Fadhil I, Fallah V, Faramarzi M, Farhangi MA, Farioli A, Farzadfar F, Fentahun N, Fernandes E, Feyissa GT, Filip I, Fischer F, Fisher JL, Force LM, Foroutan M, Freitas M, Fukumoto T, Futran ND, Gallus S, Gankpe FG, Gayesa RT, Gebrehiwot TT, Gebremeskel GG, Gedefaw GA, Gelaw BK, Geta B, Getachew S, Gezae KE, Ghafourifard M, Ghajar A, Ghashghaee A, Gholamian A, Gill PS, Ginindza TTG, Girmay A, Gizaw M, Gomez RS, Gopalani SV, Gorini G, Goulart BNG, Grada A, Ribeiro Guerra M, Guimaraes ALS, Gupta PC, Gupta R, Hadkhale K, Haj-Mirzaian A, Hamadeh RR, Hamidi S, Hanfore LK, Haro JM, Hasankhani M, Hasanzadeh A, Hassen HY, Hay RJ, Hay SI, Henok A, Henry NJ, Herteliu C, Hidru HD, Hoang CL, Hole MK, Hoogar P, Horita N, Hosgood HD, Hosseini M, Hosseinzadeh M, Hostiuc M, Hostiuc S, Househ M, Hussen MM, Ileanu B, Ilic MD, Innos K, Irvani SSN, Iseh KR, Islam SMS, Islami F, Jafari Balalami N, Jafarinia M, Jahangiry L, Jahani MA, Jahanmehr N, Jakovljevic M, James SL, Javanbakht M, Jayaraman S, Jee SH, Jenabi E, Jha RP, Jonas JB, Jonnagaddala J, Joo T, Jungari SB, Jürisson M, Kabir A, Kamangar F, Karch A, Karimi N, Karimian A, Kasaeian A, Kasahun GG, Kassa B, Kassa TD, Kassaw MW, Kaul A, Keiyoro PN, Kelbore AG, Kerbo AA, Khader YS, Khalilarjmandi M, Khan EA, Khan G, Khang YH, Khatab K, Khater A, Khayamzadeh M, Khazaee-Pool M, Khazaei S, Khoja AT, Khosravi MH, Khubchandani J, Kianipour N, Kim D, Kim YJ, Kisa A, Kisa S, Kissimova-Skarbek K, Komaki H, Koyanagi A, Krohn KJ, Bicer BK, Kugbey N, Kumar V, Kuupiel D, La Vecchia C, Lad DP, Lake EA, Lakew AM, Lal DK, Lami FH, Lan Q, Lasrado S, Lauriola P, Lazarus JV, Leigh J, Leshargie CT, Liao Y, Limenih MA, Listl S, Lopez AD, Lopukhov PD, Lunevicius R, Madadin M, Magdeldin S, El Razek HMA, Majeed A, Maleki A, Malekzadeh R, Manafi A, Manafi N, Manamo WA, Mansourian M, Mansournia MA, Mantovani LG, Maroufizadeh S, Martini SMS, Mashamba-Thompson TP, Massenburg BB, Maswabi MT, Mathur MR, McAlinden C, McKee M, Meheretu HAA, Mehrotra R, Mehta V, Meier T, Melaku YA, Meles GG, Meles HG, Melese A, Melku M, Memiah PTN, Mendoza W, Menezes RG, Merat S, Meretoja TJ, Mestrovic T, Miazgowski B, Miazgowski T, Mihretie KMM, Miller TR, Mills EJ, Mir SM, Mirzaei H, Mirzaei HR, Mishra R, Moazen B, Mohammad DK, Mohammad KA, Mohammad Y, Darwesh AM, Mohammadbeigi A, Mohammadi H, Mohammadi M, Mohammadian M, Mohammadian-Hafshejani A, Mohammadoo-Khorasani M, Mohammadpourhodki R, Mohammed AS, Mohammed JA, Mohammed S, Mohebi F, Mokdad AH, Monasta L, Moodley Y, Moosazadeh M, Moossavi M, Moradi G, Moradi-Joo M, Moradi-Lakeh M, Moradpour F, Morawska L, Morgado-da-Costa J, Morisaki N, Morrison SD, Mosapour A, Mousavi SM, Muche AA, Muhammed OSS, Musa J, Nabhan AR, Naderi M, Nagarajan AJ, Nagel G, Nahvijou A, Naik G, Najafi F, Naldi L, Nam HS, Nasiri N, Nazari J, Negoi I, Neupane S, Newcomb PA, Nggada HA, Ngunjiri JW, Nguyen CT, Nikniaz L, Ningrum DNA, Nirayo YL, Nixon MR, Nnaji CA, Nojomi M, Nosratnejad S, Shiadeh MN, Obsa MS, Ofori-Asenso R, Ogbo FA, Oh IH, Olagunju AT, Olagunju TO, Oluwasanu MM, Omonisi AE, Onwujekwe OE, Oommen AM, Oren E, Ortega-Altamirano DDV, Ota E, Otstavnov SS, Owolabi MO, P A M, Padubidri JR, Pakhale S, Pakpour AH, Pana A, Park EK, Parsian H, Pashaei T, Patel S, Patil ST, Pennini A, Pereira DM, Piccinelli C, Pillay JD, Pirestani M, Pishgar F, Postma MJ, Pourjafar H, Pourmalek F, Pourshams A, Prakash S, Prasad N, Qorbani M, Rabiee M, Rabiee N, Radfar A, Rafiei A, Rahim F, Rahimi M, Rahman MA, Rajati F, Rana SM, Raoofi S, Rath GK, Rawaf DL, Rawaf S, Reiner RC, Renzaho AMN, Rezaei N, Rezapour A, Ribeiro AI, Ribeiro D, Ronfani L, Roro EM, Roshandel G, Rostami A, Saad RS, Sabbagh P, Sabour S, Saddik B, Safiri S, Sahebkar A, Salahshoor MR, Salehi F, Salem H, Salem MR, Salimzadeh H, Salomon JA, Samy AM, Sanabria J, Santric Milicevic MM, Sartorius B, Sarveazad A, Sathian B, Satpathy M, Savic M, Sawhney M, Sayyah M, Schneider IJC, Schöttker B, Sekerija M, Sepanlou SG, Sepehrimanesh M, Seyedmousavi S, Shaahmadi F, Shabaninejad H, Shahbaz M, Shaikh MA, Shamshirian A, Shamsizadeh M, Sharafi H, Sharafi Z, Sharif M, Sharifi A, Sharifi H, Sharma R, Sheikh A, Shirkoohi R, Shukla SR, Si S, Siabani S, Silva DAS, Silveira DGA, Singh A, Singh JA, Sisay S, Sitas F, Sobngwi E, Soofi M, Soriano JB, Stathopoulou V, Sufiyan MB, Tabarés-Seisdedos R, Tabuchi T, Takahashi K, Tamtaji OR, Tarawneh MR, Tassew SG, Taymoori P, Tehrani-Banihashemi A, Temsah MH, Temsah O, Tesfay BE, Tesfay FH, Teshale MY, Tessema GA, Thapa S, Tlaye KG, Topor-Madry R, Tovani-Palone MR, Traini E, Tran BX, Tran KB, Tsadik AG, Ullah I, Uthman OA, Vacante M, Vaezi M, Varona Pérez P, Veisani Y, Vidale S, Violante FS, Vlassov V, Vollset SE, Vos T, Vosoughi K, Vu GT, Vujcic IS, Wabinga H, Wachamo TM, Wagnew FS, Waheed Y, Weldegebreal F, Weldesamuel GT, Wijeratne T, Wondafrash DZ, Wonde TE, Wondmieneh AB, Workie HM, Yadav R, Yadegar A, Yadollahpour A, Yaseri M, Yazdi-Feyzabadi V, Yeshaneh A, Yimam MA, Yimer EM, Yisma E, Yonemoto N, Younis MZ, Yousefi B, Yousefifard M, Yu C, Zabeh E, Zadnik V, Moghadam TZ, Zaidi Z, Zamani M, Zandian H, Zangeneh A, Zaki L, Zendehdel K, Zenebe ZM, Zewale TA, Ziapour A, Zodpey S, Murray CJL, Fitzmaurice C., Abate D., Abbasi N., Abbastabar H., Abd-Allah F., Abdel-Rahman O., Abdelalim A., Abdoli A., Abdollahpour I., Abdulle A.S.M., Abebe N.D., Abraha H.N., Abu-Raddad L.J., Abualhasan A., Adedeji I.A., Advani S.M., Afarideh M., Afshari M., Aghaali M., Agius D., Agrawal S., Ahmadi A., Ahmadian E., Ahmadpour E., Ahmed M.B., Akbari M.E., Akinyemiju T., Al-Aly Z., Alabdulkader A.M., Alahdab F., Alam T., Alamene G.M., Alemnew B.T.T., Alene K.A., Alinia C., Alipour V., Aljunid S.M., Bakeshei F.A., Almadi M.A.H., Almasi-Hashiani A., Alsharif U., Alsowaidi S., Alvis-Guzman N., Amini E., Amini S., Amoako Y.A., Anbari Z., Anber N.H., Andrei C.L., Anjomshoa M., Ansari F., Ansariadi A., Appiah S.C.Y., Arab-Zozani M., Arabloo J., Arefi Z., Aremu O., Areri H.A., Artaman A., Asayesh H., Asfaw E.T., Ashagre A.F., Assadi R., Ataeinia B., Atalay H.T., Ataro Z., Atique S., Ausloos M., Avila-Burgos L., Avokpaho E.F.G.A., Awasthi A., Awoke N., Ayala Quintanilla B.P., Ayanore M.A., Ayele H.T., Babaee E., Bacha U., Badawi A., Bagherzadeh M., Bagli E., Balakrishnan S., Balouchi A., Barnighausen T.W., Battista R.J., Behzadifar M., Bekele B.B., Belay Y.B., Belayneh Y.M., Berfield K.K.S., Berhane A., Bernabe E., Beuran M., Bhakta N., Bhattacharyya K., Biadgo B., Bijani A., Bin Sayeed M.S., Birungi C., Bisignano C., Bitew H., Bjorge T., Bleyer A., Bogale K.A., Bojia H.A., Borzi A.M., Bosetti C., Bou-Orm I.R., Brenner H., Brewer J.D., Briko A.N., Briko N.I., Bustamante-Teixeira M.T., Butt Z.A., Carreras G., Carrero J.J., Carvalho F., Castro C., Castro F., Catala-Lopez F., Cerin E., Chaiah Y., Chanie W.F., Chattu V.K., Chaturvedi P., Chauhan N.S., Chehrazi M., Chiang P.P.-C., Chichiabellu T.Y., Chido-Amajuoyi O.G., Chimed-Ochir O., Choi J.-Y.J., Christopher D.J., Chu D.-T., Constantin M.-M., Costa V.M., Crocetti E., Crowe C.S., Curado M.P., Dahlawi S.M.A., Damiani G., Darwish A.H., Daryani A., Das Neves J., Demeke F.M., Demis A.B., Demissie B.W., Demoz G.T., Denova-Gutierrez E., Derakhshani A., Deribe K.S., Desai R., Desalegn B.B., Desta M., Dey S., Dharmaratne S.D., Dhimal M., Diaz D., Dinberu M.T.T., Djalalinia S., Doku D.T., Drake T.M., Dubey M., Dubljanin E., Duken E.E., Ebrahimi H., Effiong A., Eftekhari A., El Sayed I., Zaki M.E.S., El-Jaafary S.I., El-Khatib Z., Elemineh D.A., Elkout H., Ellenbogen R.G., Elsharkawy A., Emamian M.H., Endalew D.A., Endries A.Y., Eshrati B., Fadhil I., Fallah V., Faramarzi M., Farhangi M.A., Farioli A., Farzadfar F., Fentahun N., Fernandes E., Feyissa G.T., Filip I., Fischer F., Fisher J.L., Force L.M., Foroutan M., Freitas M., Fukumoto T., Futran N.D., Gallus S., Gankpe F.G., Gayesa R.T., Gebrehiwot T.T., Gebremeskel G.G., Gedefaw G.A., Gelaw B.K., Geta B., Getachew S., Gezae K.E., Ghafourifard M., Ghajar A., Ghashghaee A., Gholamian A., Gill P.S., Ginindza T.T.G., Girmay A., Gizaw M., Gomez R.S., Gopalani S.V., Gorini G., Goulart B.N.G., Grada A., Ribeiro Guerra M., Guimaraes A.L.S., Gupta P.C., Gupta R., Hadkhale K., Haj-Mirzaian A., Hamadeh R.R., Hamidi S., Hanfore L.K., Haro J.M., Hasankhani M., Hasanzadeh A., Hassen H.Y., Hay R.J., Hay S.I., Henok A., Henry N.J., Herteliu C., Hidru H.D., Hoang C.L., Hole M.K., Hoogar P., Horita N., Hosgood H.D., Hosseini M., Hosseinzadeh M., Hostiuc M., Hostiuc S., Househ M., Hussen M.M., Ileanu B., Ilic M.D., Innos K., Irvani S.S.N., Iseh K.R., Islam S.M.S., Islami F., Jafari Balalami N., Jafarinia M., Jahangiry L., Jahani M.A., Jahanmehr N., Jakovljevic M., James S.L., Javanbakht M., Jayaraman S., Jee S.H., Jenabi E., Jha R.P., Jonas J.B., Jonnagaddala J., Joo T., Jungari S.B., Jurisson M., Kabir A., Kamangar F., Karch A., Karimi N., Karimian A., Kasaeian A., Kasahun G.G., Kassa B., Kassa T.D., Kassaw M.W., Kaul A., Keiyoro P.N., Kelbore A.G., Kerbo A.A., Khader Y.S., Khalilarjmandi M., Khan E.A., Khan G., Khang Y.-H., Khatab K., Khater A., Khayamzadeh M., Khazaee-Pool M., Khazaei S., Khoja A.T., Khosravi M.H., Khubchandani J., Kianipour N., Kim D., Kim Y.J., Kisa A., Kisa S., Kissimova-Skarbek K., Komaki H., Koyanagi A., Krohn K.J., Bicer B.K., Kugbey N., Kumar V., Kuupiel D., La Vecchia C., Lad D.P., Lake E.A., Lakew A.M., Lal D.K., Lami F.H., Lan Q., Lasrado S., Lauriola P., Lazarus J.V., Leigh J., Leshargie C.T., Liao Y., Limenih M.A., Listl S., Lopez A.D., Lopukhov P.D., Lunevicius R., Madadin M., Magdeldin S., El Razek H.M.A., Majeed A., Maleki A., Malekzadeh R., Manafi A., Manafi N., Manamo W.A., Mansourian M., Mansournia M.A., Mantovani L.G., Maroufizadeh S., Martini S.M.S., Mashamba-Thompson T.P., Massenburg B.B., Maswabi M.T., Mathur M.R., McAlinden C., McKee M., Meheretu H.A.A., Mehrotra R., Mehta V., Meier T., Melaku Y.A., Meles G.G., Meles H.G., Melese A., Melku M., Memiah P.T.N., Mendoza W., Menezes R.G., Merat S., Meretoja T.J., Mestrovic T., Miazgowski B., Miazgowski T., Mihretie K.M.M., Miller T.R., Mills E.J., Mir S.M., Mirzaei H., Mirzaei H.R., Mishra R., Moazen B., Mohammad D.K., Mohammad K.A., Mohammad Y., Darwesh A.M., Mohammadbeigi A., Mohammadi H., Mohammadi M., Mohammadian M., Mohammadian-Hafshejani A., Mohammadoo-Khorasani M., Mohammadpourhodki R., Mohammed A.S., Mohammed J.A., Mohammed S., Mohebi F., Mokdad A.H., Monasta L., Moodley Y., Moosazadeh M., Moossavi M., Moradi G., Moradi-Joo M., Moradi-Lakeh M., Moradpour F., Morawska L., Morgado-Da-costa J., Morisaki N., Morrison S.D., Mosapour A., Mousavi S.M., Muche A.A., Muhammed O.S.S., Musa J., Nabhan A.R., Naderi M., Nagarajan A.J., Nagel G., Nahvijou A., Naik G., Najafi F., Naldi L., Nam H.S., Nasiri N., Nazari J., Negoi I., Neupane S., Newcomb P.A., Nggada H.A., Ngunjiri J.W., Nguyen C.T., Nikniaz L., Ningrum D.N.A., Nirayo Y.L., Nixon M.R., Nnaji C.A., Nojomi M., Nosratnejad S., Shiadeh M.N., Obsa M.S., Ofori-Asenso R., Ogbo F.A., Oh I.-H., Olagunju A.T., Olagunju T.O., Oluwasanu M.M., Omonisi A.E., Onwujekwe O.E., Oommen A.M., Oren E., Ortega-Altamirano D.D.V., Ota E., Otstavnov S.S., Owolabi M.O., P A M., Padubidri J.R., Pakhale S., Pakpour A.H., Pana A., Park E.-K., Parsian H., Pashaei T., Patel S., Patil S.T., Pennini A., Pereira D.M., Piccinelli C., Pillay J.D., Pirestani M., Pishgar F., Postma M.J., Pourjafar H., Pourmalek F., Pourshams A., Prakash S., Prasad N., Qorbani M., Rabiee M., Rabiee N., Radfar A., Rafiei A., Rahim F., Rahimi M., Rahman M.A., Rajati F., Rana S.M., Raoofi S., Rath G.K., Rawaf D.L., Rawaf S., Reiner R.C., Renzaho A.M.N., Rezaei N., Rezapour A., Ribeiro A.I., Ribeiro D., Ronfani L., Roro E.M., Roshandel G., Rostami A., Saad R.S., Sabbagh P., Sabour S., Saddik B., Safiri S., Sahebkar A., Salahshoor M.R., Salehi F., Salem H., Salem M.R., Salimzadeh H., Salomon J.A., Samy A.M., Sanabria J., Santric Milicevic M.M., Sartorius B., Sarveazad A., Sathian B., Satpathy M., Savic M., Sawhney M., Sayyah M., Schneider I.J.C., Schottker B., Sekerija M., Sepanlou S.G., Sepehrimanesh M., Seyedmousavi S., Shaahmadi F., Shabaninejad H., Shahbaz M., Shaikh M.A., Shamshirian A., Shamsizadeh M., Sharafi H., Sharafi Z., Sharif M., Sharifi A., Sharifi H., Sharma R., Sheikh A., Shirkoohi R., Shukla S.R., Si S., Siabani S., Silva D.A.S., Silveira D.G.A., Singh A., Singh J.A., Sisay S., Sitas F., Sobngwi E., Soofi M., Soriano J.B., Stathopoulou V., Sufiyan M.B., Tabares-Seisdedos R., Tabuchi T., Takahashi K., Tamtaji O.R., Tarawneh M.R., Tassew S.G., Taymoori P., Tehrani-Banihashemi A., Temsah M.-H., Temsah O., Tesfay B.E., Tesfay F.H., Teshale M.Y., Tessema G.A., Thapa S., Tlaye K.G., Topor-Madry R., Tovani-Palone M.R., Traini E., Tran B.X., Tran K.B., Tsadik A.G., Ullah I., Uthman O.A., Vacante M., Vaezi M., Varona Perez P., Veisani Y., Vidale S., Violante F.S., Vlassov V., Vollset S.E., Vos T., Vosoughi K., Vu G.T., Vujcic I.S., Wabinga H., Wachamo T.M., Wagnew F.S., Waheed Y., Weldegebreal F., Weldesamuel G.T., Wijeratne T., Wondafrash D.Z., Wonde T.E., Wondmieneh A.B., Workie H.M., Yadav R., Yadegar A., Yadollahpour A., Yaseri M., Yazdi-Feyzabadi V., Yeshaneh A., Yimam M.A., Yimer E.M., Yisma E., Yonemoto N., Younis M.Z., Yousefi B., Yousefifard M., Yu C., Zabeh E., Zadnik V., Moghadam T.Z., Zaidi Z., Zamani M., Zandian H., Zangeneh A., Zaki L., Zendehdel K., Zenebe Z.M., Zewale T.A., Ziapour A., Zodpey S., Murray C.J.L., Microbes in Health and Disease (MHD), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Value, Affordability and Sustainability (VALUE), Clinicum, Doctoral Programme in Clinical Research, HUS Comprehensive Cancer Center, Institute for Molecular Medicine Finland, Fitzmaurice, C, Abate, D, Abbasi, N, Abbastabar, H, Abd-Allah, F, Abdel-Rahman, O, Abdelalim, A, Abdoli, A, Abdollahpour, I, Abdulle, A, Abebe, N, Abraha, H, Abu-Raddad, L, Abualhasan, A, Adedeji, I, Advani, S, Afarideh, M, Afshari, M, Aghaali, M, Agius, D, Agrawal, S, Ahmadi, A, Ahmadian, E, Ahmadpour, E, Ahmed, M, Akbari, M, Akinyemiju, T, Al-Aly, Z, Alabdulkader, A, Alahdab, F, Alam, T, Alamene, G, Alemnew, B, Alene, K, Alinia, C, Alipour, V, Aljunid, S, Bakeshei, F, Almadi, M, Almasi-Hashiani, A, Alsharif, U, Alsowaidi, S, Alvis-Guzman, N, Amini, E, Amini, S, Amoako, Y, Anbari, Z, Anber, N, Andrei, C, Anjomshoa, M, Ansari, F, Ansariadi, A, Appiah, S, Arab-Zozani, M, Arabloo, J, Arefi, Z, Aremu, O, Areri, H, Artaman, A, Asayesh, H, Asfaw, E, Ashagre, A, Assadi, R, Ataeinia, B, Atalay, H, Ataro, Z, Atique, S, Ausloos, M, Avila-Burgos, L, Avokpaho, E, Awasthi, A, Awoke, N, Ayala Quintanilla, B, Ayanore, M, Ayele, H, Babaee, E, Bacha, U, Badawi, A, Bagherzadeh, M, Bagli, E, Balakrishnan, S, Balouchi, A, Barnighausen, T, Battista, R, Behzadifar, M, Bekele, B, Belay, Y, Belayneh, Y, Berfield, K, Berhane, A, Bernabe, E, Beuran, M, Bhakta, N, Bhattacharyya, K, Biadgo, B, Bijani, A, Bin Sayeed, M, Birungi, C, Bisignano, C, Bitew, H, Bjorge, T, Bleyer, A, Bogale, K, Bojia, H, Borzi, A, Bosetti, C, Bou-Orm, I, Brenner, H, Brewer, J, Briko, A, Briko, N, Bustamante-Teixeira, M, Butt, Z, Carreras, G, Carrero, J, Carvalho, F, Castro, C, Castro, F, Catala-Lopez, F, Cerin, E, Chaiah, Y, Chanie, W, Chattu, V, Chaturvedi, P, Chauhan, N, Chehrazi, M, Chiang, P, Chichiabellu, T, Chido-Amajuoyi, O, Chimed-Ochir, O, Choi, J, Christopher, D, Chu, D, Constantin, M, Costa, V, Crocetti, E, Crowe, C, Curado, M, Dahlawi, S, Damiani, G, Darwish, A, Daryani, A, Das Neves, J, Demeke, F, Demis, A, Demissie, B, Demoz, G, Denova-Gutierrez, E, Derakhshani, A, Deribe, K, Desai, R, Desalegn, B, Desta, M, Dey, S, Dharmaratne, S, Dhimal, M, Diaz, D, Dinberu, M, Djalalinia, S, Doku, D, Drake, T, Dubey, M, Dubljanin, E, Duken, E, Ebrahimi, H, Effiong, A, Eftekhari, A, El Sayed, I, Zaki, M, El-Jaafary, S, El-Khatib, Z, Elemineh, D, Elkout, H, Ellenbogen, R, Elsharkawy, A, Emamian, M, Endalew, D, Endries, A, Eshrati, B, Fadhil, I, Fallah, V, Faramarzi, M, Farhangi, M, Farioli, A, Farzadfar, F, Fentahun, N, Fernandes, E, Feyissa, G, Filip, I, Fischer, F, Fisher, J, Force, L, Foroutan, M, Freitas, M, Fukumoto, T, Futran, N, Gallus, S, Gankpe, F, Gayesa, R, Gebrehiwot, T, Gebremeskel, G, Gedefaw, G, Gelaw, B, Geta, B, Getachew, S, Gezae, K, Ghafourifard, M, Ghajar, A, Ghashghaee, A, Gholamian, A, Gill, P, Ginindza, T, Girmay, A, Gizaw, M, Gomez, R, Gopalani, S, Gorini, G, Goulart, B, Grada, A, Ribeiro Guerra, M, Guimaraes, A, Gupta, P, Gupta, R, Hadkhale, K, Haj-Mirzaian, A, Hamadeh, R, Hamidi, S, Hanfore, L, Haro, J, Hasankhani, M, Hasanzadeh, A, Hassen, H, Hay, R, Hay, S, Henok, A, Henry, N, Herteliu, C, Hidru, H, Hoang, C, Hole, M, Hoogar, P, Horita, N, Hosgood, H, Hosseini, M, Hosseinzadeh, M, Hostiuc, M, Hostiuc, S, Househ, M, Hussen, M, Ileanu, B, Ilic, M, Innos, K, Irvani, S, Iseh, K, Islam, S, Islami, F, Jafari Balalami, N, Jafarinia, M, Jahangiry, L, Jahani, M, Jahanmehr, N, Jakovljevic, M, James, S, Javanbakht, M, Jayaraman, S, Jee, S, Jenabi, E, Jha, R, Jonas, J, Jonnagaddala, J, Joo, T, Jungari, S, Jurisson, M, Kabir, A, Kamangar, F, Karch, A, Karimi, N, Karimian, A, Kasaeian, A, Kasahun, G, Kassa, B, Kassa, T, Kassaw, M, Kaul, A, Keiyoro, P, Kelbore, A, Kerbo, A, Khader, Y, Khalilarjmandi, M, Khan, E, Khan, G, Khang, Y, Khatab, K, Khater, A, Khayamzadeh, M, Khazaee-Pool, M, Khazaei, S, Khoja, A, Khosravi, M, Khubchandani, J, Kianipour, N, Kim, D, Kim, Y, Kisa, A, Kisa, S, Kissimova-Skarbek, K, Komaki, H, Koyanagi, A, Krohn, K, Bicer, B, Kugbey, N, Kumar, V, Kuupiel, D, La Vecchia, C, Lad, D, Lake, E, Lakew, A, Lal, D, Lami, F, Lan, Q, Lasrado, S, Lauriola, P, Lazarus, J, Leigh, J, Leshargie, C, Liao, Y, Limenih, M, Listl, S, Lopez, A, Lopukhov, P, Lunevicius, R, Madadin, M, Magdeldin, S, El Razek, H, Majeed, A, Maleki, A, Malekzadeh, R, Manafi, A, Manafi, N, Manamo, W, Mansourian, M, Mansournia, M, Mantovani, L, Maroufizadeh, S, Martini, S, Mashamba-Thompson, T, Massenburg, B, Maswabi, M, Mathur, M, Mcalinden, C, Mckee, M, Meheretu, H, Mehrotra, R, Mehta, V, Meier, T, Melaku, Y, Meles, G, Meles, H, Melese, A, Melku, M, Memiah, P, Mendoza, W, Menezes, R, Merat, S, Meretoja, T, Mestrovic, T, Miazgowski, B, Miazgowski, T, Mihretie, K, Miller, T, Mills, E, Mir, S, Mirzaei, H, Mishra, R, Moazen, B, Mohammad, D, Mohammad, K, Mohammad, Y, Darwesh, A, Mohammadbeigi, A, Mohammadi, H, Mohammadi, M, Mohammadian, M, Mohammadian-Hafshejani, A, Mohammadoo-Khorasani, M, Mohammadpourhodki, R, Mohammed, A, Mohammed, J, Mohammed, S, Mohebi, F, Mokdad, A, Monasta, L, Moodley, Y, Moosazadeh, M, Moossavi, M, Moradi, G, Moradi-Joo, M, Moradi-Lakeh, M, Moradpour, F, Morawska, L, Morgado-Da-costa, J, Morisaki, N, Morrison, S, Mosapour, A, Mousavi, S, Muche, A, Muhammed, O, Musa, J, Nabhan, A, Naderi, M, Nagarajan, A, Nagel, G, Nahvijou, A, Naik, G, Najafi, F, Naldi, L, Nam, H, Nasiri, N, Nazari, J, Negoi, I, Neupane, S, Newcomb, P, Nggada, H, Ngunjiri, J, Nguyen, C, Nikniaz, L, Ningrum, D, Nirayo, Y, Nixon, M, Nnaji, C, Nojomi, M, Nosratnejad, S, Shiadeh, M, Obsa, M, Ofori-Asenso, R, Ogbo, F, Oh, I, Olagunju, A, Olagunju, T, Oluwasanu, M, Omonisi, A, Onwujekwe, O, Oommen, A, Oren, E, Ortega-Altamirano, D, Ota, E, Otstavnov, S, Owolabi, M, P A, M, Padubidri, J, Pakhale, S, Pakpour, A, Pana, A, Park, E, Parsian, H, Pashaei, T, Patel, S, Patil, S, Pennini, A, Pereira, D, Piccinelli, C, Pillay, J, Pirestani, M, Pishgar, F, Postma, M, Pourjafar, H, Pourmalek, F, Pourshams, A, Prakash, S, Prasad, N, Qorbani, M, Rabiee, M, Rabiee, N, Radfar, A, Rafiei, A, Rahim, F, Rahimi, M, Rahman, M, Rajati, F, Rana, S, Raoofi, S, Rath, G, Rawaf, D, Rawaf, S, Reiner, R, Renzaho, A, Rezaei, N, Rezapour, A, Ribeiro, A, Ribeiro, D, Ronfani, L, Roro, E, Roshandel, G, Rostami, A, Saad, R, Sabbagh, P, Sabour, S, Saddik, B, Safiri, S, Sahebkar, A, Salahshoor, M, Salehi, F, Salem, H, Salem, M, Salimzadeh, H, Salomon, J, Samy, A, Sanabria, J, Santric Milicevic, M, Sartorius, B, Sarveazad, A, Sathian, B, Satpathy, M, Savic, M, Sawhney, M, Sayyah, M, Schneider, I, Schottker, B, Sekerija, M, Sepanlou, S, Sepehrimanesh, M, Seyedmousavi, S, Shaahmadi, F, Shabaninejad, H, Shahbaz, M, Shaikh, M, Shamshirian, A, Shamsizadeh, M, Sharafi, H, Sharafi, Z, Sharif, M, Sharifi, A, Sharifi, H, Sharma, R, Sheikh, A, Shirkoohi, R, Shukla, S, Si, S, Siabani, S, Silva, D, Silveira, D, Singh, A, Singh, J, Sisay, S, Sitas, F, Sobngwi, E, Soofi, M, Soriano, J, Stathopoulou, V, Sufiyan, M, Tabares-Seisdedos, R, Tabuchi, T, Takahashi, K, Tamtaji, O, Tarawneh, M, Tassew, S, Taymoori, P, Tehrani-Banihashemi, A, Temsah, M, Temsah, O, Tesfay, B, Tesfay, F, Teshale, M, Tessema, G, Thapa, S, Tlaye, K, Topor-Madry, R, Tovani-Palone, M, Traini, E, Tran, B, Tran, K, Tsadik, A, Ullah, I, Uthman, O, Vacante, M, Vaezi, M, Varona Perez, P, Veisani, Y, Vidale, S, Violante, F, Vlassov, V, Vollset, S, Vos, T, Vosoughi, K, Vu, G, Vujcic, I, Wabinga, H, Wachamo, T, Wagnew, F, Waheed, Y, Weldegebreal, F, Weldesamuel, G, Wijeratne, T, Wondafrash, D, Wonde, T, Wondmieneh, A, Workie, H, Yadav, R, Yadegar, A, Yadollahpour, A, Yaseri, M, Yazdi-Feyzabadi, V, Yeshaneh, A, Yimam, M, Yimer, E, Yisma, E, Yonemoto, N, Younis, M, Yousefi, B, Yousefifard, M, Yu, C, Zabeh, E, Zadnik, V, Moghadam, T, Zaidi, Z, Zamani, M, Zandian, H, Zangeneh, A, Zaki, L, Zendehdel, K, Zenebe, Z, Zewale, T, Ziapour, A, Zodpey, S, Murray, C, Fitzmaurice, Christina, Abate, Degu, Abbasi, Naghmeh, Abbastabar, Hedayat, Yisma, Engida, Murray, Christopher JL, and Global Burden of Disease Cancer Collaboration
- Subjects
Cancer Research ,age distribution ,cancer incidence ,Colorectal cancer ,GBD, DALY ,cancer risk ,Global Health ,Global Burden of Disease ,disease burden ,cause of death ,trachea cancer ,0302 clinical medicine ,systematic review ,Neoplasms ,quality adjusted life year ,11. Sustainability ,Epidemiology ,cancer mortality ,030212 general & internal medicine ,years of life lost ,Stomach cancer ,fertility ,disabled person ,stomach cancer ,disability-adjusted life year ,nonhodgkin lymphoma ,Incidence ,1. No poverty ,prostate cancer ,3. Good health ,income ,Oncology ,risk factor ,030220 oncology & carcinogenesis ,bladder cancer ,Quality-Adjusted Life Years ,medicine.medical_specialty ,sex difference ,3122 Cancers ,colorectal cancer ,bronchus cancer ,Article ,educational status ,Causes of cancer ,liver cancer ,03 medical and health sciences ,Breast cancer ,breast cancer ,Environmental health ,geographic distribution ,medicine ,Humans ,Disabled Persons ,human ,business.industry ,Correction ,Cancer ,non melanoma skin cancer ,medicine.disease ,years lived with disability ,lung cancer ,Years of potential life lost ,Skin cancer ,global disease burden ,business ,neoplasm ,RC ,uterine cervix cancer - Abstract
Importance: Cancer and other noncommunicable diseases (NCDs) are now widely recognized as a threat to global development. The latest United Nations high-level meeting on NCDs reaffirmed this observation and also highlighted the slow progress in meeting the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases and the third Sustainable Development Goal. Lack of situational analyses, priority setting, and budgeting have been identified as major obstacles in achieving these goals. All of these have in common that they require information on the local cancer epidemiology. The Global Burden of Disease (GBD) study is uniquely poised to provide these crucial data. Objective: To describe cancer burden for 29 cancer groups in 195 countries from 1990 through 2017 to provide data needed for cancer control planning. Evidence Review: We used the GBD study estimation methods to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-Adjusted life-years (DALYs). Results are presented at the national level as well as by Socio-demographic Index (SDI), a composite indicator of income, educational attainment, and total fertility rate. We also analyzed the influence of the epidemiological vs the demographic transition on cancer incidence. Findings: In 2017, there were 24.5 million incident cancer cases worldwide (16.8 million without nonmelanoma skin cancer [NMSC]) and 9.6 million cancer deaths. The majority of cancer DALYs came from years of life lost (97%), and only 3% came from years lived with disability. The odds of developing cancer were the lowest in the low SDI quintile (1 in 7) and the highest in the high SDI quintile (1 in 2) for both sexes. In 2017, the most common incident cancers in men were NMSC (4.3 million incident cases); tracheal, bronchus, and lung (TBL) cancer (1.5 million incident cases); and prostate cancer (1.3 million incident cases). The most common causes of cancer deaths and DALYs for men were TBL cancer (1.3 million deaths and 28.4 million DALYs), liver cancer (572000 deaths and 15.2 million DALYs), and stomach cancer (542000 deaths and 12.2 million DALYs). For women in 2017, the most common incident cancers were NMSC (3.3 million incident cases), breast cancer (1.9 million incident cases), and colorectal cancer (819000 incident cases). The leading causes of cancer deaths and DALYs for women were breast cancer (601000 deaths and 17.4 million DALYs), TBL cancer (596000 deaths and 12.6 million DALYs), and colorectal cancer (414000 deaths and 8.3 million DALYs). Conclusions and Relevance: The national epidemiological profiles of cancer burden in the GBD study show large heterogeneities, which are a reflection of different exposures to risk factors, economic settings, lifestyles, and access to care and screening. The GBD study can be used by policy makers and other stakeholders to develop and improve national and local cancer control in order to achieve the global targets and improve equity in cancer care. © 2019 American Medical Association. All rights reserved.
- Published
- 2019
7. A Study on Contra-lateral Breast Dose for Various Tangential Field Techniques and Its Impact Due to Set-up Error
- Author
-
Prabhakar, R, Julka, PK, Rath, GK, Ganesh, T, Joshi, RC, Haresh, KP, Naik, KK, and Jothy Basu, KS
- Published
- 2006
8. The Best Dose Rate System of Intracavitary Brachytherapy for Cervical Carcinoma: A Comparative Study
- Author
-
Sharma, Daya Nand, Rath, Gk, Gandhi, Ak, Kumar, Pavnesh, Giridhar, Prashant, Haresh, Kp, Gupta, Subhash, and Pandey, Rambha
- Published
- 2016
- Full Text
- View/download PDF
9. Clinical and pathological response rates of docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer and comparison with anthracycline-based chemotherapies: Eight-year experience from single centre.
- Author
-
Gupta D, Raina V, Rath GK, Shukla NK, Mohanti BK, and Sharma DN
- Published
- 2011
10. Clinical outcome of patients with uterine sarcomas.
- Author
-
Sharma DN, Rath GK, Kumar S, Kumar L, Bhatla N, Gandhi AK, and Hariprasad R
- Published
- 2011
11. Tibial involvement in breast cancer: issues in diagnosis and management.
- Author
-
Goyal S, Puri T, Gupta R, Suri V, Julka PK, and Rath GK
- Abstract
Background Skeletal metastases below elbow and knee are uncommon, those to tibia are even rarer. Diagnosis may be delayed, and often confused with primary bone tumors (in solitary metastases) or with osteomyelitis or arthritis. Management depends on extent of disease and severity of symptoms. In most cases, treatment is essentially directed towards symptom relief. Method We describe a case of metastases to the tibia and foot in a case of breast cancer after a long disease-free period. Results Roentgenogram appearance mimicked osteomyelitis, which was ruled out by absence of fever, sterile cultures and no response to antibiotics. Diagnosis was established by a bone biopsy, with immunohistochemistry demonstrating a carcinoma with estrogen and progesterone receptor positivity. The patient was managed with multiagent chemotherapy, hormone therapy, bisphosphonates and palliative radiotherapy. She remained stable for 1 year after which her disease progressed with cutaneous metastases, and she was given symptomatic treatment only. Conclusion Management of acrometastases from breast cancer involves a multimodality approach. Both systemic therapy and local therapy (in the form of surgery or radiation therapy) may help. Treatment needs to be individualized depending on prognosis and extent of disease. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
12. Normal tissue complication probability of fibrosis in radiotherapy of breast cancer: accelerated partial breast irradiation vs conventional external-beam radiotherapy.
- Author
-
Jothy Basu KS, Bahl A, Subramani V, Sharma DN, Rath GK, Julka PK, Jothy Basu, K S, Bahl, Amit, Subramani, V, Sharma, D N, Rath, G K, and Julka, P K
- Abstract
Aims: Radiotherapy forms an integral part of breast-conserving treatment in early-stage breast cancer. Subcutaneous fibrosis of the treated breast is an important late effect in whole-breast irradiation. The aim of this study was to compare the normal tissue complication probability (NTCP) for radiation-induced fibrosis in treated breast using accelerated partial-breast irradiation (APBI) vs conventional treatment.Materials and Methods: Ten postoperative early-stage breast cancer patients (T1N0M0) were included in this dosimetric analysis. APBI treatment was planned using conformal radiotherapy technique and conventional treatment plans included two tangential portals. All the APBI treatment plans were made with five non-coplanar beams with 6 MV photons. The prescription dose was 38 Gy in 10 fractions for the APBI treatments and 50 Gy in 25 fractions, followed by a boost dose of 16 Gy in 8 fractions, for the conventional treatments. We used Lyman's relative-seriality model and the breast fibrosis NTCP model fitting parameters for the study.Results: The equivalent uniform dose (EUD) was 30.09 Gy and 50.79 Gy in APBI and conventional treatment, respectively. The mean NTCP values for ipsilateral breast fibrosis in APBI and conventional treatment were 0.51 and 25.66%, respectively. Using the paired t-test, a statistically significant difference was seen in the breast fibrosis NTCP values for APBI vs conventional treatment (P < 0.001).Conclusions: APBI reduces the ipsilateral breast fibrosis compared to conventional whole-breast treatment in early-stage breast cancer. [ABSTRACT FROM AUTHOR]- Published
- 2008
13. Radiofrequency ablation of hepatic metastasis: results of treatment in forty patients.
- Author
-
Rath GK, Julka PK, Thulkar S, Sharma DN, Bahl A, Bhatnagar S, Rath, G K, Julka, P K, Thulkar, S, Sharma, D N, Bahl, Amit, and Bhatnagar, S
- Abstract
Aim: To evaluate the local control of hepatic metastasis with radiofrequency ablation treatment.Materials and Methods: We did a retrospective analysis in 40 patients treated with radiofrequency ablation for hepatic metastasis. The tumors ablated included up to two metastatic liver lesions, with primaries in breast, gastrointestinal tract, cervix, etc. Radiofrequency ablation was performed under general anesthesia in all cases, using ultrasound guidance. Radionics Cool-Tip RF System was used to deliver the treatment.Results: The median age of patients treated was 49 years. There were 13 female and 27 male patients. The median tumor size ablated was 1.5 cm (0.75-4.0 cm). A total of 52 radiofrequency ablation cycles were delivered. Successful ablation was achieved in all patients with hepatic metastasis less than 3 cm in size. Pain was the most common complication seen (75%). One patients developed skin burns. At 2-year follow-up 7.5% of patients had locally recurrent disease.Conclusions: Radiofrequency ablation is a minimally invasive treatment modality. It can be useful in a select group of patients with solitary liver metastasis of less than 3 cm size. [ABSTRACT FROM AUTHOR]- Published
- 2008
14. Finger doses for staff handling radiopharmaceuticals in nuclear medicine.
- Author
-
Pant GS, Sharma SK, and Rath GK
- Published
- 2006
15. Primary spinal epidural extraosseous Ewing’s sarcoma: Report of five cases and literature review.
- Author
-
Mukhopadhyay, Partha, Mukhopadhyay, P, Gairola, M, Sharma, MC, Thulkar, S, Julka, PK, and Rath, GK
- Subjects
EWING'S sarcoma ,SPINAL cord cancer ,CLINICAL medicine - Abstract
SUMMARY Ewing’s sarcoma is the most common malignant bone tumour occurring in children and adolescents and exists in two different clinicopathological entities: osseous Ewing’s sarcoma (OES) and extraosseous Ewing’s sarcoma (EES). Five cases of primary epidural EES are described, which presented with non-specific symptoms leading to a long diagnostic delay. The median age at diagnosis was 22 years (range 13–36 years). The median diagnostic delay was 3 months. All patients had one or more neurological deficits. All underwent surgical exploration with a laminectomy and partial resection followed by adjuvant radiotherapy to a dose of 46–50 Gy and chemotherapy with VAC (vincristine, adriamycin and cyclophosphamide) alternating with ICE (ifosphamide, cisplatin and etoposide) for at least six cycles. The mean follow-up period is 21.2 months (range 11–32 months). Four of the five patients achieved a complete remission and are disease free at the time of writing this report. Two patients have a residual neurological deficit – both having presented with long history of neurological deficit. Primary spinal epidural EES should be suspected whenever young patients present with back pain and/or radicular pain, have abnormal neurology and an extradural mass is demonstrated on MRI. Surgical excision followed by adjuvant radiotherapy (50 Gy) and combination chemotherapy (VAC alternating with ICE) achieved local and systemic control in these patients. A greater number of patients and longer follow up are required to evolve a generally accepted treatment policy for this aggressive but potentially curable malignancy. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
16. A study of concurrent radiochemotherapy with paclitaxel in glioblastoma multiforme.
- Author
-
Julka, Pk, Awasthy, Bs, Rath, Gk, Agarwal, S, Varna, T, Mahapatra, Ak, and Singh, R
- Subjects
GLIOBLASTOMA multiforme treatment ,PACLITAXEL ,RADIOTHERAPY ,DRUG efficacy - Abstract
SUMMARY Despite advances in neurosurgery and radiotherapy, the prognosis of patients with glioblastoma multiforme remains poor. Reports in the literature about the radiosensitizing properties of paclitaxel stimulated the authors to conduct a study using paclitaxel concurrently with radiation in a group of 18 patients who had residual disease postoperatively. Paclitaxel was delivered weekly as an intravenous infusion in a dose of 60 mg/m
2 along with radiation to the primary lesion. A total of 108 cycles of paclitaxel was given. All the patients tolerated the treatment well. The main side effects were haematological, and neuropathy which was self-limiting. The overall 1-year survival rate was 70%, with 12 patients alive at 13 months. The median survival has not yet been reached although it is more than 13 months. Thus, paclitaxel can be safely delivered concomitantly with radiation in patients with glioblastoma multiforme. Larger, randomized trials are required to establish the comparative efficacy of paclitaxel as a radiosensitizer in glioblastoma multiforme. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
17. Clinical profile and problems of management of 108 cases of germ cell tumours of testis at Institute Rotary Cancer Hospital, All India Institute of Medical Sciences New Delhi 1985-1990.
- Author
-
Raina, V, Shukla, NK, Rath, GK, Gupta, NP, Mishra, MC, Chaterjee, TK, Kripalani, AK, Shukla, N K, Rath, G K, Gupta, N P, Mishra, M C, Chaterjee, T K, and Kripalani, A K
- Published
- 1993
- Full Text
- View/download PDF
18. Results of definitive radiotherapy in T1 and T2 glottic carcinoma: Institute of Rotary Cancer Hospital experience.
- Author
-
Mohanti, BK, Tandon, DA, Bahadur, S, Rath, GK, Tanwar, RK, Lal, P, and Biswal, BM
- Abstract
SUMMARY Early glottic carcinomas (T
1 and T2 ) constitute only 2% of all laryngeal cancers in our data. Seventy patients were seen between 1985 and 1992. All patients were treated by cobalt-60 small field radiotherapy using a beam directed shell. The total dose delivered was 60-65 Gy in 31 patients and 66-70 Gy in 39 patients. The follow-up period ranged from 5 to 126 months, with a mean follow up of 37 months overall and 55 months in the surgical salvage group. Radiation therapy controlled disease in 71% (50 of 70) of patients overall; 75% with T1 and 67% with T2 lesions. Total laryngectomy as salvage surgery was performed in 70% (14 of 20) of patients whose disease recurred. Ultimate control including surgical salvage occurred in 64 (91%) of 70 patients in the present study. The actuarial 5 year survival was 83 and 80% in T1 and T2 tumours, respectively (statistically insignificant). This report supports the policy of definitive irradiation, reserving surgical salvage for radiation failures in early laryngeal cancers. [ABSTRACT FROM AUTHOR]- Published
- 1996
- Full Text
- View/download PDF
19. A629 Myeloma: 15 Years' Experience from a Major Cancer Center in India
- Author
-
Raina, V, Sharma, A, Kumar, R, Wadhwa, J, Bhattacharya, S, Thulkar, S, Rath, GK, and Kocupillai, V
- Published
- 2009
- Full Text
- View/download PDF
20. Sarcomatoid carcinoma of the maxillary sinus: a rare head and neck tumor.
- Author
-
Kumar M, Goyal S, Bahl A, Das P, Sharma DN, Ray R, Rath GK, Kumar, Milind, Goyal, Shikha, Bahl, Amit, Das, Prasenjit, Sharma, D N, Ray, Ruma, and Rath, G K
- Abstract
Sarcomatoid carcinomas are rare tumors. These tumors have been reported at other sites, but head and neck origin is extremely uncommon. We report here a rare case of sarcomatoid carcinoma involving the maxilla. Only four such cases with maxillary origin have been discussed in English literature earlier. As compared to squamous cell carcinoma of maxilla, this variant is associated with poor prognosis and advanced disease at presentation, as was also seen in our case. There are no standard recommendations for management owing to the rarity of this histology. Surgery and radiotherapy form the mainstays of treatment. Exploration of the role of chemotherapy and novel targeted therapy agents is warranted in order to improve treatment results. [ABSTRACT FROM AUTHOR]
- Published
- 2008
21. Sarcomatoid squamous cell carcinoma of uterine cervix: pathology, imaging, and treatment.
- Author
-
Kumar M, Bahl A, Sharma DN, Agarwal S, Halanaik D, Kumar R, Rath GK, Kumar, Milind, Bahl, Amit, Sharma, Daya Nand, Agarwal, Shipra, Halanaik, Dhanapathi, Kumar, Rakesh, and Rath, Goura Kishore
- Abstract
Sarcomatoid squamous cell carcinoma of the cervix is a rare tumor. Only 16 cases have so far been reported in literature. We report here one such tumor occurring in a 54-year-old postmenopausal woman. Our case report describes the clinical, pathological, and PET scan characteristics of this tumor. The patient was treated with concurrent chemoradiotherapy and is disease free at 6-months follow-up. [ABSTRACT FROM AUTHOR]
- Published
- 2008
22. Germ cell tumours in uncorrected cryptorchid testis at Institute Rotary Cancer Hospital, New Delhi.
- Author
-
Raina, V, Shukla, NK, Gupta, NP, Deo, S, and Rath, GK
- Published
- 1995
- Full Text
- View/download PDF
23. Malignant melanoma presenting as bilateral breast masses.
- Author
-
Jayalakshmi, S, Chancier, S, Prasad, RR, Saxena, AK, Sharma, MC, and Rath, GK
- Abstract
SUMMARY Malignant melanoma presenting initially with disseminated disease is common. However, bilateral breast masses as the initial symptom of malignant melanoma are rare. One such case is detailed here, together with a review of literature. [ABSTRACT FROM AUTHOR]
- Published
- 1997
- Full Text
- View/download PDF
24. Role of transabdominal pelvic ultrasound and computed tomography in the detection of bladder involvement in advanced cancer of the cervix.
- Author
-
Deo, SVS, Shukla, NK, Sandhu, M, Thakur, KK, Goel, S, Mohanti, BK, and Rath, GK
- Abstract
SUMMARY The imaging data of 125 advanced cancer cervix patients attending the Institute Rotary Cancer Hospital between June 1992 and June 1994 was reviewed. The aim of the study was to assess the role of transabdominal pelvic ultrasound (TAPUS) and computed tomography (CT) in the detection of bladder involvement. TAPUS was performed in 65 patients (group I) and CT in 60 patients (group II). With respect to clinical stage, both groups were comparable. Cystoscopy was performed in all patients and the findings were taken as the gold standard for comparison of imaging data. The sensitivity, specificity and accuracy of TAPUS were 65, 94 and 75%, respectively, while those for CT were 80, 92 and 85%, respectively. Results of the present study reveal that the accuracy of TAPUS is comparable to the accuracy of other imaging modalities in the detection of bladder involvement in cervical cancer and that it should be used more frequently in developing countries that deal with a large number of cervical cancer patients in view of its easy availability, low cost and absence of exposure to radiation. [ABSTRACT FROM AUTHOR]
- Published
- 1996
- Full Text
- View/download PDF
25. Surgical resection with and without chemotherapy in oesophageal cancer
- Author
-
Rath, GK, Sharma, DN, and Shukla, NK
- Published
- 2002
- Full Text
- View/download PDF
26. Conversation with Dr. G. K. Rath. [Interviewed by Sapna Gupta].
- Author
-
Rath GK
- Published
- 2011
- Full Text
- View/download PDF
27. Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. In regard to Anscher MS et al. (Int J Radiat Oncol Biol Phys 2008;71:1-9)
- Author
-
Bahl A, Sharma DN, Rath GK, and Julka PK
- Published
- 2008
- Full Text
- View/download PDF
28. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
- Author
-
Stanaway, Jeffrey D., Afshin, Ashkan, Gakidou, Emmanuela, Lim, Stephen S., Abate, Degu, Abate, Kalkidan Hassen, Abbafati, Cristiana, Abbasi, Nooshin, Abbastabar, Hedayat, Abd-Allah, Foad, Abdela, Jemal, Abdelalim, Ahmed, Abdollahpour, Ibrahim, Abdulkader, Rizwan Suliankatchi, Abebe, Molla, Abebe, Zegeye, Abera, Semaw F., Abil, Olifan Zewdie, Abraha, Haftom Niguse, Abrham, Aklilu Roba, Abu-Raddad, Laith Jamal, Abu-Rmeileh, Niveen ME, Accrombessi, Manfred Mario Kokou, Acharya, Dilaram, Acharya, Pawan, Adamu, Abdu A., Adane, Akilew Awoke, Adebayo, Oladimeji M., Adedoyin, Rufus Adesoji, Adekanmbi, Victor, Ademi, Zanfina, Adetokunboh, Olatunji O., Adib, Mina G., Admasie, Amha, Adsuar, Jose C., Afanvi, Kossivi Agbelenko, Afarideh, Mohsen, Agarwal, Gina, Aggarwal, Anju, Aghayan, Sargis Aghasi, Agrawal, Anurag, Agrawal, Sutapa, Ahmadi, Alireza, Ahmadi, Mehdi, Ahmadieh, Hamid, Ahmed, Muktar Beshir, Aichour, Amani Nidhal, Aichour, Ibtihel, Aichour, Miloud Taki Eddine, Akbari, Mohammad Esmaeil, Akinyemiju, Tomi, Akseer, Nadia, Al-Aly, Ziyad, Al-Eyadhy, Ayman, Al-Mekhlafi, Hesham M., Alahdab, Fares, Alam, Khurshid, Alam, Samiah, Alam, Tahiya, Alashi, Alaa, Alavian, Seyed Moayed, Alene, Kefyalew Addis, Ali, Komal, Ali, Syed Mustafa, Alijanzadeh, Mehran, Alizadeh-Navaei, Reza, Aljunid, Syed Mohamed, Alkerwi, Ala'a, Alla, François, Alsharif, Ubai, Altirkawi, Khalid, Alvis-Guzman, Nelson, Amare, Azmeraw T., Ammar, Walid, Anber, Nahla Hamed, Anderson, Jason A., Andrei, Catalina Liliana, Androudi, Sofia, Animut, Megbaru Debalkie, Anjomshoa, Mina, Ansha, Mustafa Geleto, Antó, Josep M., Antonio, Carl Abelardo T., Anwari, Palwasha, Appiah, Lambert Tetteh, Appiah, Seth Christopher Yaw, Arabloo, Jalal, Aremu, Olatunde, Ärnlöv, Johan, Artaman, Al, Aryal, Krishna K., Asayesh, Hamid, Ataro, Zerihun, Ausloos, Marcel, Avokpaho, Euripide F.G.A., Awasthi, Ashish, Ayala Quintanilla, Beatriz Paulina, Ayer, Rakesh, Ayuk, Tambe B., Azzopardi, Peter S., Babazadeh, Arefeh, Badali, Hamid, Badawi, Alaa, Balakrishnan, Kalpana, Bali, Ayele Geleto, Ball, Kylie, Ballew, Shoshana H., Banach, Maciej, Banoub, Joseph Adel Mattar, Barac, Aleksandra, Barker-Collo, Suzanne Lyn, Bärnighausen, Till Winfried, Barrero, Lope H., Basu, Sanjay, Baune, Bernhard T., Bazargan-Hejazi, Shahrzad, Bedi, Neeraj, Beghi, Ettore, Behzadifar, Masoud, Behzadifar, Meysam, Béjot, Yannick, Bekele, Bayu Begashaw, Bekru, Eyasu Tamru, Belay, Ezra, Belay, Yihalem Abebe, Bell, Michelle L., Bello, Aminu K., Bennett, Derrick A., Bensenor, Isabela M., Bergeron, Gilles, Berhane, Adugnaw, Bernabe, Eduardo, Bernstein, Robert S., Beuran, Mircea, Beyranvand, Tina, Bhala, Neeraj, Bhalla, Ashish, Bhattarai, Suraj, Bhutta, Zulfiqar A., Biadgo, Belete, Bijani, Ali, Bikbov, Boris, Bilano, Ver, Bililign, Nigus, Bin Sayeed, Muhammad Shahdaat, Bisanzio, Donal, Biswas, Tuhin, Bjørge, Tone, Blacker, Brigette F., Bleyer, Archie, Borschmann, Rohan, Bou-Orm, Ibrahim R., Boufous, Soufiane, Bourne, Rupert, Brady, Oliver J., Brauer, Michael, Brazinova, Alexandra, Breitborde, Nicholas J.K., Brenner, Hermann, Briko, Andrey Nikolaevich, Britton, Gabrielle, Brugha, Traolach, Buchbinder, Rachelle, Burnett, Richard T., Busse, Reinhard, Butt, Zahid A., Cahill, Leah E., Cahuana-Hurtado, Lucero, Campos-Nonato, Ismael R., Cárdenas, Rosario, Carreras, Giulia, Carrero, Juan J., Carvalho, Félix, Castañeda-Orjuela, Carlos A., Castillo Rivas, Jacqueline, Castro, Franz, Catalá-López, Ferrán, Causey, Kate, Cercy, Kelly M., Cerin, Ester, Chaiah, Yazan, Chang, Hsing Yi, Chang, Jung Chen, Chang, Kai Lan, Charlson, Fiona J., Chattopadhyay, Aparajita, Chattu, Vijay Kumar, Chee, Miao Li, Cheng, Ching Yu, Chew, Adrienne, Chiang, Peggy Pei Chia, Chimed-Ochir, Odgerel, Chin, Ken Lee, Chitheer, Abdulaal, Choi, Jee Young J., Chowdhury, Rajiv, Christensen, Hanne, Christopher, Devasahayam J., Chung, Sheng Chia, Cicuttini, Flavia M., Cirillo, Massimo, Cohen, Aaron J., Collado-Mateo, Daniel, Cooper, Cyrus, Cooper, Owen R., Coresh, Josef, Cornaby, Leslie, Cortesi, Paolo Angelo, Cortinovis, Monica, Costa, Megan, Cousin, Ewerton, Criqui, Michael H., Cromwell, Elizabeth A., Cundiff, David K., Daba, Alemneh Kabeta, Dachew, Berihun Assefa, Dadi, Abel Fekadu, Damasceno, Albertino Antonio Moura, Dandona, Lalit, Dandona, Rakhi, Darby, Sarah C., Dargan, Paul I., Daryani, Ahmad, Das Gupta, Rajat, Das Neves, José, Dasa, Tamirat Tesfaye, Dash, Aditya Prasad, Davitoiu, Dragos Virgil, Davletov, Kairat, De la Cruz-Góngora, Vanessa, De La Hoz, Fernando Pio, De Leo, Diego, De Neve, Jan Walter, Degenhardt, Louisa, Deiparine, Selina, Dellavalle, Robert P., Demoz, Gebre Teklemariam, Denova-Gutiérrez, Edgar, Deribe, Kebede, Dervenis, Nikolaos, Deshpande, Aniruddha, Des Jarlais, Don C., Dessie, Getenet Ayalew, Deveber, Gabrielle Aline, Dey, Subhojit, Dharmaratne, Samath Dhamminda, Dhimal, Meghnath, Dinberu, Mesfin Tadese, Ding, Eric L., Diro, Helen Derara, Djalalinia, Shirin, Do, Huyen Phuc, Dokova, Klara, Doku, David Teye, Doyle, Kerrie E., Driscoll, Tim R., Dubey, Manisha, Dubljanin, Eleonora, Duken, Eyasu Ejeta, Duncan, Bruce B., Duraes, Andre R., Ebert, Natalie, Ebrahimi, Hedyeh, Ebrahimpour, Soheil, Edvardsson, David, Effiong, Andem, Eggen, Anne Elise, El Bcheraoui, Charbel, El-Khatib, Ziad, Elyazar, Iqbal Rf, Enayati, Ahmadali, Endries, Aman Yesuf, Er, Benjamin, Erskine, Holly E., Eskandarieh, Sharareh, Esteghamati, Alireza, Estep, Kara, Fakhim, Hamed, Faramarzi, Mahbobeh, Fareed, Mohammad, Farid, Talha A., Farinha, Carla Sofia E.sá, Farioli, Andrea, Faro, Andre, Farvid, Maryam S., Farzaei, Mohammad Hosein, Fatima, Batool, Fay, Kairsten A., Fazaeli, Ali Akbar, Feigin, Valery L., Feigl, Andrea B., Fereshtehnejad, Seyed Mohammad, Fernandes, Eduarda, Fernandes, Joao C., Ferrara, Giannina, Ferrari, Alize J., Ferreira, Manuela L., Filip, Irina, Finger, Jonas David, Fischer, Florian, Foigt, Nataliya A., Foreman, Kyle J., Fukumoto, Takeshi, Fullman, Nancy, Fürst, Thomas, Furtado, João M., Futran, Neal D., Gall, Seana, Gallus, Silvano, Gamkrelidze, Amiran, Ganji, Morsaleh, Garcia-Basteiro, Alberto L., Gardner, William M., Gebre, Abadi Kahsu, Gebremedhin, Amanuel Tesfay, Gebremichael, Teklu Gebrehiwo, Gelano, Tilayie Feto, Geleijnse, Johanna M., Geramo, Yilma Chisha Dea, Gething, Peter W., Gezae, Kebede Embaye, Ghadimi, Reza, Ghadiri, Keyghobad, Ghasemi Falavarjani, Khalil, Ghasemi-Kasman, Maryam, Ghimire, Mamata, Ghosh, Rakesh, Ghoshal, Aloke Gopal, Giampaoli, Simona, Gill, Paramjit Singh, Gill, Tiffany K., Gillum, Richard F., Ginawi, Ibrahim Abdelmageed, Giussani, Giorgia, Gnedovskaya, Elena V., Godwin, William W., Goli, Srinivas, Gómez-Dantés, Hector, Gona, Philimon N., Gopalani, Sameer Vali, Goulart, Alessandra C., Grada, Ayman, Grams, Morgan E., Grosso, Giuseppe, Gugnani, Harish Chander, Guo, Yuming, Gupta, Rahul, Gupta, Rajeev, Gupta, Tanush, Gutiérrez, Reyna Alma, Gutiérrez-Torres, Daniela S., Haagsma, Juanita A., Habtewold, Tesfa Dejenie, Hachinski, Vladimir, Hafezi-Nejad, Nima, Hagos, Tekleberhan B., Hailegiyorgis, Tewodros Tesfa, Hailu, Gessessew Bugssa, Haj-Mirzaian, Arvin, Haj-Mirzaian, Arya, Hamadeh, Randah R., Hamidi, Samer, Handal, Alexis J., Hankey, Graeme J., Hao, Yuantao, Harb, Hilda L., Harikrishnan, Sivadasanpillai, Haro, Josep Maria, Hassankhani, Hadi, Hassen, Hamid Yimam, Havmoeller, Rasmus, Hawley, Caitlin N., Hay, Simon I., Hedayatizadeh-Omran, Akbar, Heibati, Behzad, Heidari, Behnam, Heidari, Mohsen, Hendrie, Delia, Henok, Andualem, Heredia-Pi, Ileana, Herteliu, Claudiu, Heydarpour, Fatemeh, Heydarpour, Sousan, Hibstu, Desalegn T., Higazi, Tarig B., Hilawe, Esayas Haregot, Hoek, Hans W., Hoffman, Howard J., Hole, Michael K., Homaie Rad, Enayatollah, Hoogar, Praveen, Hosgood, H. Dean, Hosseini, Seyed Mostafa, Hosseinzadeh, Mehdi, Hostiuc, Mihaela, Hostiuc, Sorin, Hoy, Damian G., Hsairi, Mohamed, Hsiao, Thomas, Hu, Guoqing, Hu, Howard, Huang, John J., Hussen, Mamusha Aman, Huynh, Chantal K., Iburg, Kim Moesgaard, Ikeda, Nayu, Ilesanmi, Olayinka Stephen, Iqbal, Usman, Irvani, Seyed Sina Naghibi, Irvine, Caleb Mackay Salpeter, Islam, Sheikh Mohammed Shariful, Islami, Farhad, Jackson, Maria D., Jacobsen, Kathryn H., Jahangiry, Leila, Jahanmehr, Nader, Jain, Sudhir Kumar, Jakovljevic, Mihajlo, James, Spencer L., Jassal, Simerjot K., Jayatilleke, Achala Upendra, Jeemon, Panniyammakal, Jha, Ravi Prakash, Jha, Vivekanand, Ji, John S., Jonas, Jost B., Jonnagaddala, Jitendra, Jorjoran Shushtari, Zahra, Joshi, Ankur, Jozwiak, Jacek Jerzy, Jürisson, Mikk, Kabir, Zubair, Kahsay, Amaha, Kalani, Rizwan, Kanchan, Tanuj, Kant, Surya, Kar, Chittaranjan, Karami, Manoochehr, Karami Matin, Behzad, Karch, André, Karema, Corine, Karimi, Narges, Karimi, Seyed M., Kasaeian, Amir, Kassa, Dessalegn H., Kassa, Getachew Mullu, Kassa, Tesfaye Dessale, Kassebaum, Nicholas J., Katikireddi, Srinivasa Vittal, Kaul, Anil, Kawakami, Norito, Kazemi, Zhila, Karyani, Ali Kazemi, Kefale, Adane Teshome, Keiyoro, Peter Njenga, Kemp, Grant Rodgers, Kengne, Andre Pascal, Keren, Andre, Kesavachandran, Chandrasekharan Nair, Khader, Yousef Saleh, Khafaei, Behzad, Khafaie, Morteza Abdullatif, Khajavi, Alireza, Khalid, Nauman, Khalil, Ibrahim A., Khan, Gulfaraz, Khan, Muhammad Shahzeb, Khan, Muhammad Ali, Khang, Young Ho, Khater, Mona M., Khazaei, Mohammad, Khazaie, Habibolah, Khoja, Abdullah T., Khosravi, Ardeshir, Khosravi, Mohammad Hossein, Kiadaliri, Aliasghar A., Kiirithio, Daniel N., Kim, Cho Il, Kim, Daniel, Kim, Young Eun, Kim, Yun Jin, Kimokoti, Ruth W., Kinfu, Yohannes, Kisa, Adnan, Kissimova-Skarbek, Katarzyna, Kivimäki, Mika, Knibbs, Luke D., Knudsen, Ann Kristin Skrindo, Kochhar, Sonali, Kokubo, Yoshihiro, Kolola, Tufa, Kopec, Jacek A., Kosen, Soewarta, Koul, Parvaiz A., Koyanagi, Ai, Kravchenko, Michael A., Krishan, Kewal, Krohn, Kristopher J., Kromhout, Hans, Kuate Defo, Barthelemy, Kucuk Bicer, Burcu, Kumar, G. Anil, Kumar, Manasi, Kuzin, Igor, Kyu, Hmwe Hmwe, Lachat, Carl, Lad, Deepesh P., Lad, Sheetal D., Lafranconi, Alessandra, Lalloo, Ratilal, Lallukka, Tea, Lami, Faris Hasan, Lang, Justin J., Lansingh, Van C., Larson, Samantha Leigh, Latifi, Arman, Lazarus, Jeffrey V., Lee, Paul H., Leigh, James, Leili, Mostafa, Leshargie, Cheru Tesema, Leung, Janni, Levi, Miriam, Lewycka, Sonia, Li, Shanshan, Li, Yichong, Liang, Juan, Liang, Xiaofeng, Liao, Yu, Liben, Misgan Legesse, Lim, Lee Ling, Linn, Shai, Liu, Shiwei, Lodha, Rakesh, Logroscino, Giancarlo, Lopez, Alan D., Lorkowski, Stefan, Lotufo, Paulo A., Lozano, Rafael, Lucas, Tim C.D., Lunevicius, Raimundas, Ma, Stefan, Macarayan, Erlyn Rachelle King, Machado, Ísis Eloah, Madotto, Fabiana, Mai, Hue Thi, Majdan, Marek, Majdzadeh, Reza, Majeed, Azeem, Malekzadeh, Reza, Malta, Deborah Carvalho, Mamun, Abdullah A., Manda, Ana Laura, Manguerra, Helena, Mansournia, Mohammad Ali, Mantovani, Lorenzo Giovanni, Maravilla, Joemer C., Marcenes, Wagner, Marks, Ashley, Martin, Randall V., Martins, Sheila C.O., Martins-Melo, Francisco Rogerlândio, März, Winfried, Marzan, Melvin B., Massenburg, Benjamin Ballard, Mathur, Manu Raj, Mathur, Prashant, Matsushita, Kunihiro, Maulik, Pallab K., Mazidi, Mohsen, McAlinden, Colm, McGrath, John J., McKee, Martin, Mehrotra, Ravi, Mehta, Kala M., Mehta, Varshil, Meier, Toni, Mekonnen, Fantahun Ayenew, Melaku, Yohannes A., Melese, Addisu, Melku, Mulugeta, Memiah, Peter T.N., Memish, Ziad A., Mendoza, Walter, Mengistu, Desalegn Tadese, Mensah, George A., Mensink, Gert B.M., Mereta, Seid Tiku, Meretoja, Atte, Meretoja, Tuomo J., Mestrovic, Tomislav, Mezgebe, Haftay Berhane, Miazgowski, Bartosz, Miazgowski, Tomasz, Millear, Anoushka I., Miller, Ted R., Miller-Petrie, Molly Katherine, Mini, G. K., Mirarefin, Mojde, Mirica, Andreea, Mirrakhimov, Erkin M., Misganaw, Awoke Temesgen, Mitiku, Habtamu, Moazen, Babak, Mohajer, Bahram, Mohammad, Karzan Abdulmuhsin, Mohammadi, Moslem, Mohammadifard, Noushin, Mohammadnia-Afrouzi, Mousa, Mohammed, Shafiu, Mohebi, Farnam, Mokdad, Ali H., Molokhia, Mariam, Momeniha, Fatemeh, Monasta, Lorenzo, Moodley, Yoshan, Moradi, Ghobad, Moradi-Lakeh, Maziar, Moradinazar, Mehdi, Moraga, Paula, Morawska, Lidia, Morgado-Da-Costa, Joana, Morrison, Shane Douglas, Moschos, Marilita M., Mouodi, Simin, Mousavi, Seyyed Meysam, Mozaffarian, Dariush, Mruts, Kalayu Brhane, Muche, Achenef Asmamaw, Muchie, Kindie Fentahun, Mueller, Ulrich Otto, Muhammed, Oumer Sada, Mukhopadhyay, Satinath, Muller, Kate, Musa, Kamarul Imran, Mustafa, Ghulam, Nabhan, Ashraf F., Naghavi, Mohsen, Naheed, Aliya, Nahvijou, Azin, Naik, Gurudatta, Naik, Nitish, Najafi, Farid, Nangia, Vinay, Nansseu, Jobert Richie, Nascimento, Bruno Ramos, Neal, Bruce, Neamati, Nahid, Negoi, Ionut, Negoi, Ruxandra Irina, Neupane, Subas, Newton, Charles Richard James, Ngunjiri, Josephine W., Nguyen, Anh Quynh, Nguyen, Grant, Nguyen, Ha Thu, Nguyen, Huong Lan Thi, Nguyen, Huong Thanh, Nguyen, Minh, Nguyen, Nam Ba, Nichols, Emma, Nie, Jing, Ningrum, Dina Nur Anggraini, Nirayo, Yirga Legesse, Nishi, Nobuo, Nixon, Molly R., Nojomi, Marzieh, Nomura, Shuhei, Norheim, Ole F., Noroozi, Mehdi, Norrving, Bo, Noubiap, Jean Jacques, Nouri, Hamid Reza, Nourollahpour Shiadeh, Malihe, Nowroozi, Mohammad Reza, Nsoesie, Elaine O., Nyasulu, Peter S., Obermeyer, Carla M., Odell, Christopher M., Ofori-Asenso, Richard, Ogbo, Felix Akpojene, Oh, In Hwan, Oladimeji, Olanrewaju, Olagunju, Andrew T., Olagunju, Tinuke O., Olivares, Pedro R., Olsen, Helen Elizabeth, Olusanya, Bolajoko Olubukunola, Olusanya, Jacob Olusegun, Ong, Kanyin L., Ong, Sok King, Oren, Eyal, Orpana, Heather M., Ortiz, Alberto, Ota, Erika, Otstavnov, Stanislav S., Øverland, Simon, Owolabi, Mayowa Ojo, P A, Mahesh, Pacella, Rosana, Pakhare, Abhijit P., Pakpour, Amir H., Pana, Adrian, Panda-Jonas, Songhomitra, Park, Eun Kee, Parry, Charles D.H., Parsian, Hadi, Patel, Shanti, Pati, Sanghamitra, Patil, Snehal T., Patle, Ajay, Patton, George C., Paudel, Deepak, Paulson, Katherine R., Paz Ballesteros, Wayra Citlali, Pearce, Neil, Pereira, Alexandre, Pereira, David M., Perico, Norberto, Pesudovs, Konrad, Petzold, Max, Pham, Hai Quang, Phillips, Michael R., Pillay, Julian David, Piradov, Michael A., Pirsaheb, Meghdad, Pischon, Tobias, Pishgar, Farhad, Plana-Ripoll, Oleguer, Plass, Dietrich, Polinder, Suzanne, Polkinghorne, Kevan R., Postma, Maarten J., Poulton, Richie, Pourshams, Akram, Poustchi, Hossein, Prabhakaran, Dorairaj, Prakash, Swayam, Prasad, Narayan, Purcell, Caroline A., Purwar, Manorama B., Qorbani, Mostafa, Radfar, Amir, Rafay, Anwar, Rafiei, Alireza, Rahim, Fakher, Rahimi, Zohreh, Rahimi-Movaghar, Afarin, Rahimi-Movaghar, Vafa, Rahman, Mahfuzar, Rahman, Mohammad Hifz ur, Rahman, Muhammad Aziz, Rai, Rajesh Kumar, Rajati, Fatemeh, Rajsic, Sasa, Raju, Sree Bhushan, Ram, Usha, Ranabhat, Chhabi Lal, Ranjan, Prabhat, Rath, Goura Kishor, Rawaf, David Laith, Rawaf, Salman, Reddy, K. Srinath, Rehm, Colin D., Rehm, Jürgen, Reiner, Robert C., Reitsma, Marissa B., Remuzzi, Giuseppe, Renzaho, Andre M.N., Resnikoff, Serge, Reynales-Shigematsu, Luz Myriam, Rezaei, Satar, Ribeiro, Antonio Luiz P., Rivera, Juan A., Roba, Kedir Teji, Rodríguez-Ramírez, Sonia, Roever, Leonardo, Román, Yesenia, Ronfani, Luca, Roshandel, Gholamreza, Rostami, Ali, Roth, Gregory A., Rothenbacher, Dietrich, Roy, Ambuj, Rubagotti, Enrico, Rushton, Lesley, Sabanayagam, Charumathi, Sachdev, Perminder S., Saddik, Basema, Sadeghi, Ehsan, Saeedi Moghaddam, Sahar, Safari, Hosein, Safari, Yahya, Safari-Faramani, Roya, Safdarian, Mahdi, Safi, Sare, Safiri, Saeid, Sagar, Rajesh, Sahebkar, Amirhossein, Sahraian, Mohammad Ali, Sajadi, Haniye Sadat, Salam, Nasir, Salamati, Payman, Saleem, Zikria, Salimi, Yahya, Salimzadeh, Hamideh, Salomon, Joshua A., Salvi, Devashri Digvijay, Salz, Inbal, Samy, Abdallah M., Sanabria, Juan, Sanchez-Niño, Maria Dolores, Sánchez-Pimienta, Tania G., Sanders, Taren, Sang, Yingying, Santomauro, Damian Francesco, Santos, Itamar S., Santos, João Vasco, Santric Milicevic, Milena M., Sao Jose, Bruno Piassi, Sardana, Mayank, Sarker, Abdur Razzaque, Sarmiento-Suárez, Rodrigo, Sarrafzadegan, Nizal, Sartorius, Benn, Sarvi, Shahabeddin, Sathian, Brijesh, Satpathy, Maheswar, Sawant, Arundhati R., Sawhney, Monika, Saylan, Mete, Sayyah, Mehdi, Schaeffner, Elke, Schmidt, Maria Inês, Schneider, Ione J.C., Schöttker, Ben, Schutte, Aletta Elisabeth, Schwebel, David C., Schwendicke, Falk, Scott, James G., Seedat, Soraya, Sekerija, Mario, Sepanlou, Sadaf G., Serre, Marc L., Serván-Mori, Edson, Seyedmousavi, Seyedmojtaba, Shabaninejad, Hosein, Shaddick, Gavin, Shafieesabet, Azadeh, Shahbazi, Mehdi, Shaheen, Amira A., Shaikh, Masood Ali, Shamah Levy, Teresa, Shams-Beyranvand, Mehran, Shamsi, Mohammadbagher, Sharafi, Heidar, Sharafi, Kiomars, Sharif, Mehdi, Sharif-Alhoseini, Mahdi, Sharifi, Hamid, Sharma, Jayendra, Sharma, Meenakshi, Sharma, Rajesh, She, Jun, Sheikh, Aziz, Shi, Peilin, Shibuya, Kenji, Shiferaw, Mekonnen Sisay, Shigematsu, Mika, Shin, Min Jeong, Shiri, Rahman, Shirkoohi, Reza, Shiue, Ivy, Shokraneh, Farhad, Shoman, Haitham, Shrime, Mark G., Shupler, Matthew S., Si, Si, Siabani, Soraya, Sibai, Abla Mehio, Siddiqi, Tariq J., Sigfusdottir, Inga Dora, Sigurvinsdottir, Rannveig, Silva, Diego Augusto Santos, Silva, João Pedro, Silveira, Dayane Gabriele Alves, Singh, Jasvinder A., Singh, Narinder Pal, Singh, Virendra, Sinha, Dhirendra Narain, Skiadaresi, Eirini, Skirbekk, Vegard, Smith, David L., Smith, Mari, Sobaih, Badr Hasan, Sobhani, Soheila, Somayaji, Ranjani, Soofi, Moslem, Sorensen, Reed J.D., Soriano, Joan B., Soyiri, Ireneous N., Spinelli, Angela, Sposato, Luciano A., Sreeramareddy, Chandrashekhar T., Srinivasan, Vinay, Starodubov, Vladimir I., Steckling, Nadine, Stein, Dan J., Stein, Murray B., Stevanovic, Goran, Stockfelt, Leo, Stokes, Mark A., Sturua, Lela, Subart, Michelle L., Sudaryanto, Agus, Sufiyan, Mu'awiyyah Babale, Sulo, Gerhard, Sunguya, Bruno F., Sur, Patrick John, Sykes, Bryan L., Szoeke, Cassandra E.I., Tabarés-Seisdedos, Rafael, Tabuchi, Takahiro, Tadakamadla, Santosh Kumar, Takahashi, Ken, Tandon, Nikhil, Tassew, Segen Gebremeskel, Tavakkoli, Mohammad, Taveira, Nuno, Tehrani-Banihashemi, Arash, Tekalign, Tigist Gashaw, Tekelemedhin, Shishay Wahdey, Tekle, Merhawi Gebremedhin, Temesgen, Habtamu, Temsah, Mohamad Hani, Temsah, Omar, Terkawi, Abdullah Sulieman, Tessema, Belay, Teweldemedhin, Mebrahtu, Thankappan, Kavumpurathu Raman, Theis, Andrew, Thirunavukkarasu, Sathish, Thomas, Hannah J., Thomas, Matthew Lloyd, Thomas, Nihal, Thurston, George D., Tilahun, Binyam, Tillmann, Taavi, To, Quyen G., Tobollik, Myriam, Tonelli, Marcello, Topor-Madry, Roman, Torre, Anna E., Tortajada-Girbés, Miguel, Touvier, Mathilde, Tovani-Palone, Marcos Roberto, Towbin, Jeffrey A., Tran, Bach Xuan, Tran, Khanh Bao, Truelsen, Thomas Clement, Truong, Nu Thi, Tsadik, Afewerki Gebremeskel, Tudor Car, Lorainne, Tuzcu, E. Murat, Tymeson, Hayley D., Tyrovolas, Stefanos, Ukwaja, Kingsley N., Ullah, Irfan, Updike, Rachel L., Usman, Muhammad Shariq, Uthman, Olalekan A., Vaduganathan, Muthiah, Vaezi, Afsane, Valdez, Pascual R., Van Donkelaar, Aaron, Varavikova, Elena, Varughese, Santosh, Vasankari, Tommi Juhani, Venkateswaran, Vidhya, Venketasubramanian, Narayanaswamy, Villafaina, Santos, Violante, Francesco S., Vladimirov, Sergey Konstantinovitch, Vlassov, Vasily, Vollset, Stein Emil, Vos, Theo, Vosoughi, Kia, Vu, Giang Thu, Vujcic, Isidora S., Wagnew, Fasil Shiferaw, Waheed, Yasir, Waller, Stephen G., Walson, Judd L., Wang, Yafeng, Wang, Yanping, Wang, Yuan Pang, Weiderpass, Elisabete, Weintraub, Robert G., Weldegebreal, Fitsum, Werdecker, Andrea, Werkneh, Adhena Ayaliew, West, J. Jason, Westerman, Ronny, Whiteford, Harvey A., Widecka, Justyna, Wijeratne, Tissa, Winkler, Andrea Sylvia, Wiyeh, Alison B., Wiysonge, Charles Shey, Wolfe, Charles D.A., Wong, Tien Yin, Wu, Shouling, Xavier, Denis, Xu, Gelin, Yadgir, Simon, Yadollahpour, Ali, Yahyazadeh Jabbari, Seyed Hossein, Yamada, Tomohide, Yan, Lijing L., Yano, Yuichiro, Yaseri, Mehdi, Yasin, Yasin Jemal, Yeshaneh, Alex, Yimer, Ebrahim M., Yip, Paul, Yisma, Engida, Yonemoto, Naohiro, Yoon, Seok Jun, Yotebieng, Marcel, Younis, Mustafa Z., Yousefifard, Mahmoud, Yu, Chuanhua, Zaidi, Zoubida, Zaman, Sojib Bin, Zamani, Mohammad, Zavala-Arciniega, Luis, Zhang, Anthony Lin, Zhang, Hao, Zhang, Kai, Zhou, Maigeng, Zimsen, Stephanie R.M., Zodpey, Sanjay, Murray, Christopher J.L., Sub Cond-Matter Theory, Stat & Comp Phys, Sub Atmospheric physics and chemistry, One Health Chemisch, dIRAS RA-2, Afd Chemical Biology and Drug Discovery, Stanaway, J, Afshin, A, Gakidou, E, Lim, S, Abate, D, Abate, K, Abbafati, C, Abbasi, N, Abbastabar, H, Abd-Allah, F, Abdela, J, Abdelalim, A, Abdollahpour, I, Abdulkader, R, Abebe, M, Abebe, Z, Abera, S, Abil, O, Abraha, H, Abrham, A, Abu-Raddad, L, Abu-Rmeileh, N, Accrombessi, M, Acharya, D, Acharya, P, Adamu, A, Adane, A, Adebayo, O, Adedoyin, R, Adekanmbi, V, Ademi, Z, Adetokunboh, O, Adib, M, Admasie, A, Adsuar, J, Afanvi, K, Afarideh, M, Agarwal, G, Aggarwal, A, Aghayan, S, Agrawal, A, Agrawal, S, Ahmadi, A, Ahmadi, M, Ahmadieh, H, Ahmed, M, Aichour, A, Aichour, I, Aichour, M, Akbari, M, Akinyemiju, T, Akseer, N, Al-Aly, Z, Al-Eyadhy, A, Al-Mekhlafi, H, Alahdab, F, Alam, K, Alam, S, Alam, T, Alashi, A, Alavian, S, Alene, K, Ali, K, Ali, S, Alijanzadeh, M, Alizadeh-Navaei, R, Aljunid, S, Alkerwi, A, Alla, F, Alsharif, U, Altirkawi, K, Alvis-Guzman, N, Amare, A, Ammar, W, Anber, N, Anderson, J, Andrei, C, Androudi, S, Animut, M, Anjomshoa, M, Ansha, M, Antó, J, Antonio, C, Anwari, P, Appiah, L, Appiah, S, Arabloo, J, Aremu, O, Ärnlöv, J, Artaman, A, Aryal, K, Asayesh, H, Ataro, Z, Ausloos, M, Avokpaho, E, Awasthi, A, Ayala Quintanilla, B, Ayer, R, Ayuk, T, Azzopardi, P, Babazadeh, A, Badali, H, Badawi, A, Balakrishnan, K, Bali, A, Ball, K, Ballew, S, Banach, M, Banoub, J, Barac, A, Barker-Collo, S, Bärnighausen, T, Barrero, L, Basu, S, Baune, B, Bazargan-Hejazi, S, Bedi, N, Beghi, E, Behzadifar, M, Béjot, Y, Bekele, B, Bekru, E, Belay, E, Belay, Y, Bell, M, Bello, A, Bennett, D, Bensenor, I, Bergeron, G, Berhane, A, Bernabe, E, Bernstein, R, Beuran, M, Beyranvand, T, Bhala, N, Bhalla, A, Bhattarai, S, Bhutta, Z, Biadgo, B, Bijani, A, Bikbov, B, Bilano, V, Bililign, N, Bin Sayeed, M, Bisanzio, D, Biswas, T, Bjørge, T, Blacker, B, Bleyer, A, Borschmann, R, Bou-Orm, I, Boufous, S, Bourne, R, Brady, O, Brauer, M, Brazinova, A, Breitborde, N, Brenner, H, Briko, A, Britton, G, Brugha, T, Buchbinder, R, Burnett, R, Busse, R, Butt, Z, Cahill, L, Cahuana-Hurtado, L, Campos-Nonato, I, Cárdenas, R, Carreras, G, Carrero, J, Carvalho, F, Castañeda-Orjuela, C, Castillo Rivas, J, Castro, F, Catalá-López, F, Causey, K, Cercy, K, Cerin, E, Chaiah, Y, Chang, H, Chang, J, Chang, K, Charlson, F, Chattopadhyay, A, Chattu, V, Chee, M, Cheng, C, Chew, A, Chiang, P, Chimed-Ochir, O, Chin, K, Chitheer, A, Choi, J, Chowdhury, R, Christensen, H, Christopher, D, Chung, S, Cicuttini, F, Cirillo, M, Cohen, A, Collado-Mateo, D, Cooper, C, Cooper, O, Coresh, J, Cornaby, L, Cortesi, P, Cortinovis, M, Costa, M, Cousin, E, Criqui, M, Cromwell, E, Cundiff, D, Daba, A, Dachew, B, Dadi, A, Damasceno, A, Dandona, L, Dandona, R, Darby, S, Dargan, P, Daryani, A, Das Gupta, R, Das Neves, J, Dasa, T, Dash, A, Davitoiu, D, Davletov, K, De la Cruz-Góngora, V, De La Hoz, F, De Leo, D, De Neve, J, Degenhardt, L, Deiparine, S, Dellavalle, R, Demoz, G, Denova-Gutiérrez, E, Deribe, K, Dervenis, N, Deshpande, A, Des Jarlais, D, Dessie, G, Deveber, G, Dey, S, Dharmaratne, S, Dhimal, M, Dinberu, M, Ding, E, Diro, H, Djalalinia, S, Do, H, Dokova, K, Doku, D, Doyle, K, Driscoll, T, Dubey, M, Dubljanin, E, Duken, E, Duncan, B, Duraes, A, Ebert, N, Ebrahimi, H, Ebrahimpour, S, Edvardsson, D, Effiong, A, Eggen, A, El Bcheraoui, C, El-Khatib, Z, Elyazar, I, Enayati, A, Endries, A, Er, B, Erskine, H, Eskandarieh, S, Esteghamati, A, Estep, K, Fakhim, H, Faramarzi, M, Fareed, M, Farid, T, Farinha, C, Farioli, A, Faro, A, Farvid, M, Farzaei, M, Fatima, B, Fay, K, Fazaeli, A, Feigin, V, Feigl, A, Fereshtehnejad, S, Fernandes, E, Fernandes, J, Ferrara, G, Ferrari, A, Ferreira, M, Filip, I, Finger, J, Fischer, F, Foigt, N, Foreman, K, Fukumoto, T, Fullman, N, Fürst, T, Furtado, J, Futran, N, Gall, S, Gallus, S, Gamkrelidze, A, Ganji, M, Garcia-Basteiro, A, Gardner, W, Gebre, A, Gebremedhin, A, Gebremichael, T, Gelano, T, Geleijnse, J, Geramo, Y, Gething, P, Gezae, K, Ghadimi, R, Ghadiri, K, Ghasemi Falavarjani, K, Ghasemi-Kasman, M, Ghimire, M, Ghosh, R, Ghoshal, A, Giampaoli, S, Gill, P, Gill, T, Gillum, R, Ginawi, I, Giussani, G, Gnedovskaya, E, Godwin, W, Goli, S, Gómez-Dantés, H, Gona, P, Gopalani, S, Goulart, A, Grada, A, Grams, M, Grosso, G, Gugnani, H, Guo, Y, Gupta, R, Gupta, T, Gutiérrez, R, Gutiérrez-Torres, D, Haagsma, J, Habtewold, T, Hachinski, V, Hafezi-Nejad, N, Hagos, T, Hailegiyorgis, T, Hailu, G, Haj-Mirzaian, A, Hamadeh, R, Hamidi, S, Handal, A, Hankey, G, Hao, Y, Harb, H, Harikrishnan, S, Haro, J, Hassankhani, H, Hassen, H, Havmoeller, R, Hawley, C, Hay, S, Hedayatizadeh-Omran, A, Heibati, B, Heidari, B, Heidari, M, Hendrie, D, Henok, A, Heredia-Pi, I, Herteliu, C, Heydarpour, F, Heydarpour, S, Hibstu, D, Higazi, T, Hilawe, E, Hoek, H, Hoffman, H, Hole, M, Homaie Rad, E, Hoogar, P, Hosgood, H, Hosseini, S, Hosseinzadeh, M, Hostiuc, M, Hostiuc, S, Hoy, D, Hsairi, M, Hsiao, T, Hu, G, Hu, H, Huang, J, Hussen, M, Huynh, C, Iburg, K, Ikeda, N, Ilesanmi, O, Iqbal, U, Irvani, S, Irvine, C, Islam, S, Islami, F, Jackson, M, Jacobsen, K, Jahangiry, L, Jahanmehr, N, Jain, S, Jakovljevic, M, James, S, Jassal, S, Jayatilleke, A, Jeemon, P, Jha, R, Jha, V, Ji, J, Jonas, J, Jonnagaddala, J, Jorjoran Shushtari, Z, Joshi, A, Jozwiak, J, Jürisson, M, Kabir, Z, Kahsay, A, Kalani, R, Kanchan, T, Kant, S, Kar, C, Karami, M, Karami Matin, B, Karch, A, Karema, C, Karimi, N, Karimi, S, Kasaeian, A, Kassa, D, Kassa, G, Kassa, T, Kassebaum, N, Katikireddi, S, Kaul, A, Kawakami, N, Kazemi, Z, Karyani, A, Kefale, A, Keiyoro, P, Kemp, G, Kengne, A, Keren, A, Kesavachandran, C, Khader, Y, Khafaei, B, Khafaie, M, Khajavi, A, Khalid, N, Khalil, I, Khan, G, Khan, M, Khang, Y, Khater, M, Khazaei, M, Khazaie, H, Khoja, A, Khosravi, A, Khosravi, M, Kiadaliri, A, Kiirithio, D, Kim, C, Kim, D, Kim, Y, Kimokoti, R, Kinfu, Y, Kisa, A, Kissimova-Skarbek, K, Kivimäki, M, Knibbs, L, Knudsen, A, Kochhar, S, Kokubo, Y, Kolola, T, Kopec, J, Kosen, S, Koul, P, Koyanagi, A, Kravchenko, M, Krishan, K, Krohn, K, Kromhout, H, Kuate Defo, B, Kucuk Bicer, B, Kumar, G, Kumar, M, Kuzin, I, Kyu, H, Lachat, C, Lad, D, Lad, S, Lafranconi, A, Lalloo, R, Lallukka, T, Lami, F, Lang, J, Lansingh, V, Larson, S, Latifi, A, Lazarus, J, Lee, P, Leigh, J, Leili, M, Leshargie, C, Leung, J, Levi, M, Lewycka, S, Li, S, Li, Y, Liang, J, Liang, X, Liao, Y, Liben, M, Lim, L, Linn, S, Liu, S, Lodha, R, Logroscino, G, Lopez, A, Lorkowski, S, Lotufo, P, Lozano, R, Lucas, T, Lunevicius, R, Ma, S, Macarayan, E, Machado, Í, Madotto, F, Mai, H, Majdan, M, Majdzadeh, R, Majeed, A, Malekzadeh, R, Malta, D, Mamun, A, Manda, A, Manguerra, H, Mansournia, M, Mantovani, L, Maravilla, J, Marcenes, W, Marks, A, Martin, R, Martins, S, Martins-Melo, F, März, W, Marzan, M, Massenburg, B, Mathur, M, Mathur, P, Matsushita, K, Maulik, P, Mazidi, M, Mcalinden, C, Mcgrath, J, Mckee, M, Mehrotra, R, Mehta, K, Mehta, V, Meier, T, Mekonnen, F, Melaku, Y, Melese, A, Melku, M, Memiah, P, Memish, Z, Mendoza, W, Mengistu, D, Mensah, G, Mensink, G, Mereta, S, Meretoja, A, Meretoja, T, Mestrovic, T, Mezgebe, H, Miazgowski, B, Miazgowski, T, Millear, A, Miller, T, Miller-Petrie, M, Mini, G, Mirarefin, M, Mirica, A, Mirrakhimov, E, Misganaw, A, Mitiku, H, Moazen, B, Mohajer, B, Mohammad, K, Mohammadi, M, Mohammadifard, N, Mohammadnia-Afrouzi, M, Mohammed, S, Mohebi, F, Mokdad, A, Molokhia, M, Momeniha, F, Monasta, L, Moodley, Y, Moradi, G, Moradi-Lakeh, M, Moradinazar, M, Moraga, P, Morawska, L, Morgado-Da-Costa, J, Morrison, S, Moschos, M, Mouodi, S, Mousavi, S, Mozaffarian, D, Mruts, K, Muche, A, Muchie, K, Mueller, U, Muhammed, O, Mukhopadhyay, S, Muller, K, Musa, K, Mustafa, G, Nabhan, A, Naghavi, M, Naheed, A, Nahvijou, A, Naik, G, Naik, N, Najafi, F, Nangia, V, Nansseu, J, Nascimento, B, Neal, B, Neamati, N, Negoi, I, Negoi, R, Neupane, S, Newton, C, Ngunjiri, J, Nguyen, A, Nguyen, G, Nguyen, H, Nguyen, M, Nguyen, N, Nichols, E, Nie, J, Ningrum, D, Nirayo, Y, Nishi, N, Nixon, M, Nojomi, M, Nomura, S, Norheim, O, Noroozi, M, Norrving, B, Noubiap, J, Nouri, H, Nourollahpour Shiadeh, M, Nowroozi, M, Nsoesie, E, Nyasulu, P, Obermeyer, C, Odell, C, Ofori-Asenso, R, Ogbo, F, Oh, I, Oladimeji, O, Olagunju, A, Olagunju, T, Olivares, P, Olsen, H, Olusanya, B, Olusanya, J, Ong, K, Ong, S, Oren, E, Orpana, H, Ortiz, A, Ota, E, Otstavnov, S, Øverland, S, Owolabi, M, P A, M, Pacella, R, Pakhare, A, Pakpour, A, Pana, A, Panda-Jonas, S, Park, E, Parry, C, Parsian, H, Patel, S, Pati, S, Patil, S, Patle, A, Patton, G, Paudel, D, Paulson, K, Paz Ballesteros, W, Pearce, N, Pereira, A, Pereira, D, Perico, N, Pesudovs, K, Petzold, M, Pham, H, Phillips, M, Pillay, J, Piradov, M, Pirsaheb, M, Pischon, T, Pishgar, F, Plana-Ripoll, O, Plass, D, Polinder, S, Polkinghorne, K, Postma, M, Poulton, R, Pourshams, A, Poustchi, H, Prabhakaran, D, Prakash, S, Prasad, N, Purcell, C, Purwar, M, Qorbani, M, Radfar, A, Rafay, A, Rafiei, A, Rahim, F, Rahimi, Z, Rahimi-Movaghar, A, Rahimi-Movaghar, V, Rahman, M, Rai, R, Rajati, F, Rajsic, S, Raju, S, Ram, U, Ranabhat, C, Ranjan, P, Rath, G, Rawaf, D, Rawaf, S, Reddy, K, Rehm, C, Rehm, J, Reiner, R, Reitsma, M, Remuzzi, G, Renzaho, A, Resnikoff, S, Reynales-Shigematsu, L, Rezaei, S, Ribeiro, A, Rivera, J, Roba, K, Rodríguez-Ramírez, S, Roever, L, Román, Y, Ronfani, L, Roshandel, G, Rostami, A, Roth, G, Rothenbacher, D, Roy, A, Rubagotti, E, Rushton, L, Sabanayagam, C, Sachdev, P, Saddik, B, Sadeghi, E, Saeedi Moghaddam, S, Safari, H, Safari, Y, Safari-Faramani, R, Safdarian, M, Safi, S, Safiri, S, Sagar, R, Sahebkar, A, Sahraian, M, Sajadi, H, Salam, N, Salamati, P, Saleem, Z, Salimi, Y, Salimzadeh, H, Salomon, J, Salvi, D, Salz, I, Samy, A, Sanabria, J, Sanchez-Niño, M, Sánchez-Pimienta, T, Sanders, T, Sang, Y, Santomauro, D, Santos, I, Santos, J, Santric Milicevic, M, Sao Jose, B, Sardana, M, Sarker, A, Sarmiento-Suárez, R, Sarrafzadegan, N, Sartorius, B, Sarvi, S, Sathian, B, Satpathy, M, Sawant, A, Sawhney, M, Saylan, M, Sayyah, M, Schaeffner, E, Schmidt, M, Schneider, I, Schöttker, B, Schutte, A, Schwebel, D, Schwendicke, F, Scott, J, Seedat, S, Sekerija, M, Sepanlou, S, Serre, M, Serván-Mori, E, Seyedmousavi, S, Shabaninejad, H, Shaddick, G, Shafieesabet, A, Shahbazi, M, Shaheen, A, Shaikh, M, Shamah Levy, T, Shams-Beyranvand, M, Shamsi, M, Sharafi, H, Sharafi, K, Sharif, M, Sharif-Alhoseini, M, Sharifi, H, Sharma, J, Sharma, M, Sharma, R, She, J, Sheikh, A, Shi, P, Shibuya, K, Shiferaw, M, Shigematsu, M, Shin, M, Shiri, R, Shirkoohi, R, Shiue, I, Shokraneh, F, Shoman, H, Shrime, M, Shupler, M, Si, S, Siabani, S, Sibai, A, Siddiqi, T, Sigfusdottir, I, Sigurvinsdottir, R, Silva, D, Silva, J, Silveira, D, Singh, J, Singh, N, Singh, V, Sinha, D, Skiadaresi, E, Skirbekk, V, Smith, D, Smith, M, Sobaih, B, Sobhani, S, Somayaji, R, Soofi, M, Sorensen, R, Soriano, J, Soyiri, I, Spinelli, A, Sposato, L, Sreeramareddy, C, Srinivasan, V, Starodubov, V, Steckling, N, Stein, D, Stein, M, Stevanovic, G, Stockfelt, L, Stokes, M, Sturua, L, Subart, M, Sudaryanto, A, Sufiyan, M, Sulo, G, Sunguya, B, Sur, P, Sykes, B, Szoeke, C, Tabarés-Seisdedos, R, Tabuchi, T, Tadakamadla, S, Takahashi, K, Tandon, N, Tassew, S, Tavakkoli, M, Taveira, N, Tehrani-Banihashemi, A, Tekalign, T, Tekelemedhin, S, Tekle, M, Temesgen, H, Temsah, M, Temsah, O, Terkawi, A, Tessema, B, Teweldemedhin, M, Thankappan, K, Theis, A, Thirunavukkarasu, S, Thomas, H, Thomas, M, Thomas, N, Thurston, G, Tilahun, B, Tillmann, T, To, Q, Tobollik, M, Tonelli, M, Topor-Madry, R, Torre, A, Tortajada-Girbés, M, Touvier, M, Tovani-Palone, M, Towbin, J, Tran, B, Tran, K, Truelsen, T, Truong, N, Tsadik, A, Tudor Car, L, Tuzcu, E, Tymeson, H, Tyrovolas, S, Ukwaja, K, Ullah, I, Updike, R, Usman, M, Uthman, O, Vaduganathan, M, Vaezi, A, Valdez, P, Van Donkelaar, A, Varavikova, E, Varughese, S, Vasankari, T, Venkateswaran, V, Venketasubramanian, N, Villafaina, S, Violante, F, Vladimirov, S, Vlassov, V, Vollset, S, Vos, T, Vosoughi, K, Vu, G, Vujcic, I, Wagnew, F, Waheed, Y, Waller, S, Walson, J, Wang, Y, Weiderpass, E, Weintraub, R, Weldegebreal, F, Werdecker, A, Werkneh, A, West, J, Westerman, R, Whiteford, H, Widecka, J, Wijeratne, T, Winkler, A, Wiyeh, A, Wiysonge, C, Wolfe, C, Wong, T, Wu, S, Xavier, D, Xu, G, Yadgir, S, Yadollahpour, A, Yahyazadeh Jabbari, S, Yamada, T, Yan, L, Yano, Y, Yaseri, M, Yasin, Y, Yeshaneh, A, Yimer, E, Yip, P, Yisma, E, Yonemoto, N, Yoon, S, Yotebieng, M, Younis, M, Yousefifard, M, Yu, C, Zaidi, Z, Zaman, S, Zamani, M, Zavala-Arciniega, L, Zhang, A, Zhang, H, Zhang, K, Zhou, M, Zimsen, S, Zodpey, S, Murray, C, Kardiyoloji, Sub Cond-Matter Theory, Stat & Comp Phys, Sub Atmospheric physics and chemistry, One Health Chemisch, dIRAS RA-2, Afd Chemical Biology and Drug Discovery, Stanaway, Jd, Abate, Kh, Abera, Sf, Abil, Oz, Abraha, Hn, Abrham, Ar, Abu-Raddad, Lj, Abu-Rmeileh, Nm, Accrombessi, Mmk, Adamu, Aa, Adane, Aa, Adebayo, Om, Adedoyin, Ra, Adetokunboh, Oo, Adib, Mg, Adsuar, Jc, Afanvi, Ka, Aghayan, Sa, Ahmed, Mb, Aichour, An, Aichour, Mte, Akbari, Me, Al-Mekhlafi, Hm, Alavian, Sm, Alene, Ka, Ali, Sm, Aljunid, Sm, Amare, At, Anber, Nh, Anderson, Ja, Andrei, Cl, Animut, Md, Ansha, Mg, Antó, Jm, Antonio, Cat, Appiah, Lt, Appiah, Scy, Aryal, Kk, Avokpaho, Efga, Ayala Quintanilla, Bp, Ayuk, Tb, Bali, Ag, Ballew, Sh, Banoub, Jam, Barker-Collo, Sl, Bärnighausen, Tw, Barrero, Lh, Baune, Bt, Bekele, Bb, Bekru, Et, Belay, Ya, Bell, Ml, Bello, Ak, Bennett, Da, Bensenor, Im, Bhutta, Za, Blacker, Bf, Bou-Orm, Ir, Brady, Oj, Breitborde, Njk, Briko, An, Burnett, Rt, Butt, Za, Cahill, Le, Campos-Nonato, Ir, Carrero, Jj, Castañeda-Orjuela, Ca, Cercy, Km, Chang, Hy, Chang, Jc, Chang, Kl, Charlson, Fj, Chattu, Vk, Chee, Ml, Cheng, Cy, Chiang, Pp, Chin, Kl, Choi, Jj, Christopher, Dj, Chung, Sc, Cicuttini, Fm, Cohen, Aj, Cooper, Or, Cortesi, Pa, Criqui, Mh, Cromwell, Ea, Cundiff, Dk, Daba, Ak, Dachew, Ba, Dadi, Af, Damasceno, Aam, Darby, Sc, Dargan, Pi, Dasa, Tt, Dash, Ap, Davitoiu, Dv, De La Hoz, Fp, De Neve, Jw, Dellavalle, Rp, Demoz, Gt, Des Jarlais, Dc, Dessie, Ga, Deveber, Ga, Dharmaratne, Sd, Dinberu, Mt, Ding, El, Diro, Hd, Do, Hp, Doku, Dt, Doyle, Ke, Driscoll, Tr, Duken, Ee, Duncan, Bb, Duraes, Ar, Eggen, Ae, Elyazar, Ir, Endries, Ay, Erskine, He, Farid, Ta, Farinha, Cse, Farzaei, Mh, Fay, Ka, Fazaeli, Aa, Feigin, Vl, Feigl, Ab, Fereshtehnejad, Sm, Fernandes, Jc, Ferrari, Aj, Ferreira, Ml, Finger, Jd, Foigt, Na, Foreman, Kj, Furtado, Jm, Futran, Nd, Garcia-Basteiro, Al, Gardner, Wm, Gebre, Ak, Gebremedhin, At, Gebremichael, Tg, Gelano, Tf, Geleijnse, Jm, Geramo, Ycd, Gething, Pw, Gezae, Ke, Ghoshal, Ag, Gill, Tk, Gillum, Rf, Ginawi, Ia, Gnedovskaya, Ev, Godwin, Ww, Gona, Pn, Gopalani, Sv, Goulart, Ac, Grams, Me, Gugnani, Hc, Gutiérrez, Ra, Haagsma, Ja, Habtewold, Td, Hagos, Tb, Hailegiyorgis, Tt, Hailu, Gb, Hamadeh, Rr, Handal, Aj, Hankey, Gj, Harb, Hl, Haro, Jm, Hassen, Hy, Hawley, Cn, Hay, Si, Hibstu, Dt, Higazi, Tb, Hilawe, Eh, Hoek, Hw, Hoffman, Hj, Hole, Mk, Hosgood, Hd, Hosseini, Sm, Hoy, Dg, Huang, Jj, Hussen, Ma, Huynh, Ck, Iburg, Km, Irvani, Ssn, Irvine, Cm, Islam, Sm, Jackson, Md, Jacobsen, Kh, Jain, Sk, James, Sl, Jassal, Sk, Jayatilleke, Au, Jha, Rp, Jonas, Jb, Jozwiak, Jj, Karimi, Sm, Kassa, Dh, Kassa, Gm, Kassa, Td, Kassebaum, Nj, Katikireddi, Sv, Karyani, Ak, Kefale, At, Keiyoro, Pn, Kemp, Gr, Kengne, Ap, Kesavachandran, Cn, Khafaie, Ma, Khalil, Ia, Khan, Ma, Khang, Yh, Khater, Mm, Khoja, At, Khosravi, Mh, Kiadaliri, Aa, Kiirithio, Dn, Kim, Ci, Kim, Ye, Kim, Yj, Kimokoti, Rw, Knibbs, Ld, Knudsen, Ak, Kopec, Ja, Koul, Pa, Kravchenko, Ma, Krohn, Kj, Kumar, Ga, Kyu, Hh, Lad, Dp, Lad, Sd, Lami, Fh, Lang, Jj, Lansingh, Vc, Larson, Sl, Lazarus, Jv, Lee, Ph, Leshargie, Ct, Liben, Ml, Lim, Ll, Lopez, Ad, Lotufo, Pa, Lucas, Tcd, Macarayan, Erk, Machado, Íe, Mai, Ht, Malta, Dc, Mamun, Aa, Manda, Al, Mansournia, Ma, Mantovani, Lg, Maravilla, Jc, Martin, Rv, Martins, Sco, Martins-Melo, Fr, Marzan, Mb, Massenburg, Bb, Mathur, Mr, Maulik, Pk, Mcgrath, Jj, Mehta, Km, Mekonnen, Fa, Melaku, Ya, Memiah, Ptn, Memish, Za, Mengistu, Dt, Mensah, Ga, Mensink, Gbm, Mereta, St, Meretoja, Tj, Mezgebe, Hb, Millear, Ai, Miller, Tr, Miller-Petrie, Mk, Mini, Gk, Mirrakhimov, Em, Misganaw, At, Mohammad, Ka, Mokdad, Ah, Morrison, Sd, Moschos, Mm, Mousavi, Sm, Mruts, Kb, Muche, Aa, Muchie, Kf, Mueller, Uo, Musa, Ki, Nabhan, Af, Nansseu, Jr, Nascimento, Br, Negoi, Ri, Newton, Crj, Ngunjiri, Jw, Nguyen, Aq, Nguyen, Ht, Nguyen, Hlt, Nguyen, Nb, Ningrum, Dna, Nirayo, Yl, Nixon, Mr, Norheim, Of, Noubiap, Jj, Nouri, Hr, Nowroozi, Mr, Nsoesie, Eo, Obermeyer, Cm, Odell, Cm, Ogbo, Fa, Oh, Ih, Olagunju, At, Olagunju, To, Olivares, Pr, Olsen, He, Olusanya, Bo, Olusanya, Jo, Ong, Kl, Ong, Sk, Orpana, Hm, Owolabi, Mo, Pakhare, Ap, Pakpour, Ah, Park, Ek, Parry, Cdh, Patil, St, Patton, Gc, Paulson, Kr, Paz Ballesteros, Wc, Pereira, Dm, Pham, Hq, Phillips, Mr, Pillay, Jd, Piradov, Ma, Polkinghorne, Kr, Postma, Mj, Purcell, Ca, Purwar, Mb, Rahman, Mhu, Rahman, Ma, Rai, Rk, Raju, Sb, Ranabhat, Cl, Rath, Gk, Rawaf, Dl, Rehm, Cd, Reiner RC, Jr, Reitsma, Mb, Renzaho, Amn, Reynales-Shigematsu, Lm, Ribeiro, Alp, Rivera, Ja, Roba, Kt, Roth, Ga, Sahraian, Ma, Salomon, Ja, Salvi, Dd, Samy, Am, Sanchez-Niño, Md, Sánchez-Pimienta, Tg, Santomauro, Df, Santos, Jv, Santric Milicevic, Mm, Sao Jose, Bp, Sarker, Ar, Sawant, Ar, Schmidt, Mi, Schneider, Ijc, Schutte, Ae, Schwebel, Dc, Scott, Jg, Sepanlou, Sg, Serre, Ml, Shaheen, Aa, Shaikh, Ma, Shin, Mj, Shrime, Mg, Sibai, Am, Siddiqi, Tj, Sigfusdottir, Id, Silva, Da, Silva, Jp, Silveira, Dga, Singh, Ja, Singh, Np, Sinha, Dn, Smith, Dl, Sobaih, Bh, Sorensen, Rjd, Soriano, Jb, Soyiri, In, Sposato, La, Sreeramareddy, Ct, Starodubov, Vi, Stein, Dj, Stein, Mb, Stokes, Ma, Subart, Ml, Sufiyan, Mb, Sunguya, Bf, Sur, Pj, Sykes, Bl, Szoeke, Cei, Tadakamadla, Sk, Tassew, Sg, Tekalign, Tg, Tekelemedhin, Sw, Tekle, Mg, Temsah, Mh, Thankappan, Kr, Thomas, Hj, Thomas, Ml, Thurston, Gd, To, Qg, Torre, Ae, Tovani-Palone, Mr, Towbin, Ja, Tran, Bx, Tran, Kb, Truelsen, Tc, Truong, Nt, Tsadik, Ag, Tuzcu, Em, Tymeson, Hd, Ukwaja, Kn, Updike, Rl, Uthman, Oa, Valdez, Pr, Vasankari, Tj, Vladimirov, Sk, Vollset, Se, Vu, Gt, Waller, Sg, Walson, Jl, Wang, Yp, Weintraub, Rg, Werkneh, Aa, West, Jj, Whiteford, Ha, Wiyeh, Ab, Wolfe, Cda, Wong, Ty, Yahyazadeh Jabbari, Sh, Yan, Ll, Yasin, Yj, Yimer, Em, Yoon, Sj, Younis, Mz, Zaman, Sb, Zhang, Al, Zimsen, Srm, Murray, Cjl., Stanaway, Jeffrey D, Afshin, Ashkan, Gakidou, Emmanuela, Lim, Stephen S, Abate, Degu, Abate, Kalkidan Hassen, Abbafati, Cristiana, Abbasi, Nooshin, Abbastabar, Hedayat, Abd-Allah, Foad, Abdela, Jemal, Abdelalim, Ahmed, Abdollahpour, Ibrahim, Abdulkader, Rizwan Suliankatchi, Abebe, Molla, Abebe, Zegeye, Abera, Semaw F, Abil, Olifan Zewdie, Abraha, Haftom Niguse, Abrham, Aklilu Roba, Abu-Raddad, Laith Jamal, Abu-Rmeileh, Niveen ME, Accrombessi, Manfred Mario Kokou, Acharya, Dilaram, Acharya, Pawan, Adamu, Abdu A, Adane, Akilew Awoke, Adebayo, Oladimeji M, Adedoyin, Rufus Adesoji, Adekanmbi, Victor, Ademi, Zanfina, Adetokunboh, Olatunji O, Adib, Mina G, Admasie, Amha, Adsuar, Jose C, Afanvi, Kossivi Agbelenko, Afarideh, Mohsen, Agarwal, Gina, Aggarwal, Anju, Aghayan, Sargis Aghasi, Agrawal, Anurag, Agrawal, Sutapa, Ahmadi, Alireza, Ahmadi, Mehdi, Ahmadieh, Hamid, Ahmed, Muktar Beshir, Aichour, Amani Nidhal, Aichour, Ibtihel, Aichour, Miloud Taki Eddine, Akbari, Mohammad Esmaeil, Akinyemiju, Tomi, Akseer, Nadia, Al-Aly, Ziyad, Al-Eyadhy, Ayman, Al-Mekhlafi, Hesham M, Alahdab, Fare, Alam, Khurshid, Alam, Samiah, Alam, Tahiya, Alashi, Alaa, Alavian, Seyed Moayed, Alene, Kefyalew Addi, Ali, Komal, Ali, Syed Mustafa, Alijanzadeh, Mehran, Alizadeh-Navaei, Reza, Aljunid, Syed Mohamed, Alkerwi, Ala'a, Alla, Françoi, Alsharif, Ubai, Altirkawi, Khalid, Alvis-Guzman, Nelson, Amare, Azmeraw T, Ammar, Walid, Anber, Nahla Hamed, Anderson, Jason A, Andrei, Catalina Liliana, Androudi, Sofia, Animut, Megbaru Debalkie, Anjomshoa, Mina, Ansha, Mustafa Geleto, Antó, Josep M, Antonio, Carl Abelardo T, Anwari, Palwasha, Appiah, Lambert Tetteh, Appiah, Seth Christopher Yaw, Arabloo, Jalal, Aremu, Olatunde, Ärnlöv, Johan, Artaman, Al, Aryal, Krishna K, Asayesh, Hamid, Ataro, Zerihun, Ausloos, Marcel, Avokpaho, Euripide F G A, Awasthi, Ashish, Ayala Quintanilla, Beatriz Paulina, Ayer, Rakesh, Ayuk, Tambe B, Azzopardi, Peter S, Babazadeh, Arefeh, Badali, Hamid, Badawi, Alaa, Balakrishnan, Kalpana, Bali, Ayele Geleto, Ball, Kylie, Ballew, Shoshana H, Banach, Maciej, Banoub, Joseph Adel Mattar, Barac, Aleksandra, Barker-Collo, Suzanne Lyn, Bärnighausen, Till Winfried, Barrero, Lope H, Basu, Sanjay, Baune, Bernhard T, Bazargan-Hejazi, Shahrzad, Bedi, Neeraj, Beghi, Ettore, Behzadifar, Masoud, Behzadifar, Meysam, Béjot, Yannick, Bekele, Bayu Begashaw, Bekru, Eyasu Tamru, Belay, Ezra, Belay, Yihalem Abebe, Bell, Michelle L, Bello, Aminu K, Bennett, Derrick A, Bensenor, Isabela M, Bergeron, Gille, Berhane, Adugnaw, Bernabe, Eduardo, Bernstein, Robert S, Beuran, Mircea, Beyranvand, Tina, Bhala, Neeraj, Bhalla, Ashish, Bhattarai, Suraj, Bhutta, Zulfiqar A, Biadgo, Belete, Bijani, Ali, Bikbov, Bori, Bilano, Ver, Bililign, Nigu, Bin Sayeed, Muhammad Shahdaat, Bisanzio, Donal, Biswas, Tuhin, Bjørge, Tone, Blacker, Brigette F, Bleyer, Archie, Borschmann, Rohan, Bou-Orm, Ibrahim R, Boufous, Soufiane, Bourne, Rupert, Brady, Oliver J, Brauer, Michael, Brazinova, Alexandra, Breitborde, Nicholas J K, Brenner, Hermann, Briko, Andrey Nikolaevich, Britton, Gabrielle, Brugha, Traolach, Buchbinder, Rachelle, Burnett, Richard T, Busse, Reinhard, Butt, Zahid A, Cahill, Leah E, Cahuana-Hurtado, Lucero, Campos-Nonato, Ismael R, Cárdenas, Rosario, Carreras, Giulia, Carrero, Juan J, Carvalho, Félix, Castañeda-Orjuela, Carlos A, Castillo Rivas, Jacqueline, Castro, Franz, Catalá-López, Ferrán, Causey, Kate, Cercy, Kelly M, Cerin, Ester, Chaiah, Yazan, Chang, Hsing-Yi, Chang, Jung-Chen, Chang, Kai-Lan, Charlson, Fiona J, Chattopadhyay, Aparajita, Chattu, Vijay Kumar, Chee, Miao Li, Cheng, Ching-Yu, Chew, Adrienne, Chiang, Peggy Pei-Chia, Chimed-Ochir, Odgerel, Chin, Ken Lee, Chitheer, Abdulaal, Choi, Jee-Young J, Chowdhury, Rajiv, Christensen, Hanne, Christopher, Devasahayam J, Chung, Sheng-Chia, Cicuttini, Flavia M, Cirillo, Massimo, Cohen, Aaron J, Collado-Mateo, Daniel, Cooper, Cyru, Cooper, Owen R, Coresh, Josef, Cornaby, Leslie, Cortesi, Paolo Angelo, Cortinovis, Monica, Costa, Megan, Cousin, Ewerton, Criqui, Michael H, Cromwell, Elizabeth A, Cundiff, David K, Daba, Alemneh Kabeta, Dachew, Berihun Assefa, Dadi, Abel Fekadu, Damasceno, Albertino Antonio Moura, Dandona, Lalit, Dandona, Rakhi, Darby, Sarah C, Dargan, Paul I, Daryani, Ahmad, Das Gupta, Rajat, Das Neves, José, Dasa, Tamirat Tesfaye, Dash, Aditya Prasad, Davitoiu, Dragos Virgil, Davletov, Kairat, De la Cruz-Góngora, Vanessa, De La Hoz, Fernando Pio, De Leo, Diego, De Neve, Jan-Walter, Degenhardt, Louisa, Deiparine, Selina, Dellavalle, Robert P, Demoz, Gebre Teklemariam, Denova-Gutiérrez, Edgar, Deribe, Kebede, Dervenis, Nikolao, Deshpande, Aniruddha, Des Jarlais, Don C, Dessie, Getenet Ayalew, Deveber, Gabrielle Aline, Dey, Subhojit, Dharmaratne, Samath Dhamminda, Dhimal, Meghnath, Dinberu, Mesfin Tadese, Ding, Eric L, Diro, Helen Derara, Djalalinia, Shirin, Do, Huyen Phuc, Dokova, Klara, Doku, David Teye, Doyle, Kerrie E, Driscoll, Tim R, Dubey, Manisha, Dubljanin, Eleonora, Duken, Eyasu Ejeta, Duncan, Bruce B, Duraes, Andre R, Ebert, Natalie, Ebrahimi, Hedyeh, Ebrahimpour, Soheil, Edvardsson, David, Effiong, Andem, Eggen, Anne Elise, El Bcheraoui, Charbel, El-Khatib, Ziad, Elyazar, Iqbal Rf, Enayati, Ahmadali, Endries, Aman Yesuf, Er, Benjamin, Erskine, Holly E, Eskandarieh, Sharareh, Esteghamati, Alireza, Estep, Kara, Fakhim, Hamed, Faramarzi, Mahbobeh, Fareed, Mohammad, Farid, Talha A, Farinha, Carla Sofia E sá, Farioli, Andrea, Faro, Andre, Farvid, Maryam S, Farzaei, Mohammad Hosein, Fatima, Batool, Fay, Kairsten A, Fazaeli, Ali Akbar, Feigin, Valery L, Feigl, Andrea B, Fereshtehnejad, Seyed-Mohammad, Fernandes, Eduarda, Fernandes, Joao C, Ferrara, Giannina, Ferrari, Alize J, Ferreira, Manuela L, Filip, Irina, Finger, Jonas David, Fischer, Florian, Foigt, Nataliya A, Foreman, Kyle J, Fukumoto, Takeshi, Fullman, Nancy, Fürst, Thoma, Furtado, João M, Futran, Neal D, Gall, Seana, Gallus, Silvano, Gamkrelidze, Amiran, Ganji, Morsaleh, Garcia-Basteiro, Alberto L, Gardner, William M, Gebre, Abadi Kahsu, Gebremedhin, Amanuel Tesfay, Gebremichael, Teklu Gebrehiwo, Gelano, Tilayie Feto, Geleijnse, Johanna M, Geramo, Yilma Chisha Dea, Gething, Peter W, Gezae, Kebede Embaye, Ghadimi, Reza, Ghadiri, Keyghobad, Ghasemi Falavarjani, Khalil, Ghasemi-Kasman, Maryam, Ghimire, Mamata, Ghosh, Rakesh, Ghoshal, Aloke Gopal, Giampaoli, Simona, Gill, Paramjit Singh, Gill, Tiffany K, Gillum, Richard F, Ginawi, Ibrahim Abdelmageed, Giussani, Giorgia, Gnedovskaya, Elena V, Godwin, William W, Goli, Sriniva, Gómez-Dantés, Hector, Gona, Philimon N, Gopalani, Sameer Vali, Goulart, Alessandra C, Grada, Ayman, Grams, Morgan E, Grosso, Giuseppe, Gugnani, Harish Chander, Guo, Yuming, Gupta, Rahul, Gupta, Rajeev, Gupta, Tanush, Gutiérrez, Reyna Alma, Gutiérrez-Torres, Daniela S, Haagsma, Juanita A, Habtewold, Tesfa Dejenie, Hachinski, Vladimir, Hafezi-Nejad, Nima, Hagos, Tekleberhan B, Hailegiyorgis, Tewodros Tesfa, Hailu, Gessessew Bugssa, Haj-Mirzaian, Arvin, Haj-Mirzaian, Arya, Hamadeh, Randah R, Hamidi, Samer, Handal, Alexis J, Hankey, Graeme J, Hao, Yuantao, Harb, Hilda L, Harikrishnan, Sivadasanpillai, Haro, Josep Maria, Hassankhani, Hadi, Hassen, Hamid Yimam, Havmoeller, Rasmu, Hawley, Caitlin N, Hay, Simon I, Hedayatizadeh-Omran, Akbar, Heibati, Behzad, Heidari, Behnam, Heidari, Mohsen, Hendrie, Delia, Henok, Andualem, Heredia-Pi, Ileana, Herteliu, Claudiu, Heydarpour, Fatemeh, Heydarpour, Sousan, Hibstu, Desalegn T, Higazi, Tarig B, Hilawe, Esayas Haregot, Hoek, Hans W, Hoffman, Howard J, Hole, Michael K, Homaie Rad, Enayatollah, Hoogar, Praveen, Hosgood, H Dean, Hosseini, Seyed Mostafa, Hosseinzadeh, Mehdi, Hostiuc, Mihaela, Hostiuc, Sorin, Hoy, Damian G, Hsairi, Mohamed, Hsiao, Thoma, Hu, Guoqing, Hu, Howard, Huang, John J, Hussen, Mamusha Aman, Huynh, Chantal K, Iburg, Kim Moesgaard, Ikeda, Nayu, Ilesanmi, Olayinka Stephen, Iqbal, Usman, Irvani, Seyed Sina Naghibi, Irvine, Caleb Mackay Salpeter, Islam, Sheikh Mohammed Shariful, Islami, Farhad, Jackson, Maria D, Jacobsen, Kathryn H, Jahangiry, Leila, Jahanmehr, Nader, Jain, Sudhir Kumar, Jakovljevic, Mihajlo, James, Spencer L, Jassal, Simerjot K, Jayatilleke, Achala Upendra, Jeemon, Panniyammakal, Jha, Ravi Prakash, Jha, Vivekanand, Ji, John S, Jonas, Jost B, Jonnagaddala, Jitendra, Jorjoran Shushtari, Zahra, Joshi, Ankur, Jozwiak, Jacek Jerzy, Jürisson, Mikk, Kabir, Zubair, Kahsay, Amaha, Kalani, Rizwan, Kanchan, Tanuj, Kant, Surya, Kar, Chittaranjan, Karami, Manoochehr, Karami Matin, Behzad, Karch, André, Karema, Corine, Karimi, Narge, Karimi, Seyed M, Kasaeian, Amir, Kassa, Dessalegn H, Kassa, Getachew Mullu, Kassa, Tesfaye Dessale, Kassebaum, Nicholas J, Katikireddi, Srinivasa Vittal, Kaul, Anil, Kawakami, Norito, Kazemi, Zhila, Karyani, Ali Kazemi, Kefale, Adane Teshome, Keiyoro, Peter Njenga, Kemp, Grant Rodger, Kengne, Andre Pascal, Keren, Andre, Kesavachandran, Chandrasekharan Nair, Khader, Yousef Saleh, Khafaei, Behzad, Khafaie, Morteza Abdullatif, Khajavi, Alireza, Khalid, Nauman, Khalil, Ibrahim A, Khan, Gulfaraz, Khan, Muhammad Shahzeb, Khan, Muhammad Ali, Khang, Young-Ho, Khater, Mona M, Khazaei, Mohammad, Khazaie, Habibolah, Khoja, Abdullah T, Khosravi, Ardeshir, Khosravi, Mohammad Hossein, Kiadaliri, Aliasghar A, Kiirithio, Daniel N, Kim, Cho-Il, Kim, Daniel, Kim, Young-Eun, Kim, Yun Jin, Kimokoti, Ruth W, Kinfu, Yohanne, Kisa, Adnan, Kissimova-Skarbek, Katarzyna, Kivimäki, Mika, Knibbs, Luke D, Knudsen, Ann Kristin Skrindo, Kochhar, Sonali, Kokubo, Yoshihiro, Kolola, Tufa, Kopec, Jacek A, Kosen, Soewarta, Koul, Parvaiz A, Koyanagi, Ai, Kravchenko, Michael A, Krishan, Kewal, Krohn, Kristopher J, Kromhout, Han, Kuate Defo, Barthelemy, Kucuk Bicer, Burcu, Kumar, G Anil, Kumar, Manasi, Kuzin, Igor, Kyu, Hmwe Hmwe, Lachat, Carl, Lad, Deepesh P, Lad, Sheetal D, Lafranconi, Alessandra, Lalloo, Ratilal, Lallukka, Tea, Lami, Faris Hasan, Lang, Justin J, Lansingh, Van C, Larson, Samantha Leigh, Latifi, Arman, Lazarus, Jeffrey V, Lee, Paul H, Leigh, Jame, Leili, Mostafa, Leshargie, Cheru Tesema, Leung, Janni, Levi, Miriam, Lewycka, Sonia, Li, Shanshan, Li, Yichong, Liang, Juan, Liang, Xiaofeng, Liao, Yu, Liben, Misgan Legesse, Lim, Lee-Ling, Linn, Shai, Liu, Shiwei, Lodha, Rakesh, Logroscino, Giancarlo, Lopez, Alan D, Lorkowski, Stefan, Lotufo, Paulo A, Lozano, Rafael, Lucas, Tim C D, Lunevicius, Raimunda, Ma, Stefan, Macarayan, Erlyn Rachelle King, Machado, Ísis Eloah, Madotto, Fabiana, Mai, Hue Thi, Majdan, Marek, Majdzadeh, Reza, Majeed, Azeem, Malekzadeh, Reza, Malta, Deborah Carvalho, Mamun, Abdullah A, Manda, Ana-Laura, Manguerra, Helena, Mansournia, Mohammad Ali, Mantovani, Lorenzo Giovanni, Maravilla, Joemer C, Marcenes, Wagner, Marks, Ashley, Martin, Randall V, Martins, Sheila C O, Martins-Melo, Francisco Rogerlândio, März, Winfried, Marzan, Melvin B, Massenburg, Benjamin Ballard, Mathur, Manu Raj, Mathur, Prashant, Matsushita, Kunihiro, Maulik, Pallab K, Mazidi, Mohsen, McAlinden, Colm, McGrath, John J, McKee, Martin, Mehrotra, Ravi, Mehta, Kala M, Mehta, Varshil, Meier, Toni, Mekonnen, Fantahun Ayenew, Melaku, Yohannes A, Melese, Addisu, Melku, Mulugeta, Memiah, Peter T N, Memish, Ziad A, Mendoza, Walter, Mengistu, Desalegn Tadese, Mensah, George A, Mensink, Gert B M, Mereta, Seid Tiku, Meretoja, Atte, Meretoja, Tuomo J, Mestrovic, Tomislav, Mezgebe, Haftay Berhane, Miazgowski, Bartosz, Miazgowski, Tomasz, Millear, Anoushka I, Miller, Ted R, Miller-Petrie, Molly Katherine, Mini, G.K., Mirarefin, Mojde, Mirica, Andreea, Mirrakhimov, Erkin M, Misganaw, Awoke Temesgen, Mitiku, Habtamu, Moazen, Babak, Mohajer, Bahram, Mohammad, Karzan Abdulmuhsin, Mohammadi, Moslem, Mohammadifard, Noushin, Mohammadnia-Afrouzi, Mousa, Mohammed, Shafiu, Mohebi, Farnam, Mokdad, Ali H, Molokhia, Mariam, Momeniha, Fatemeh, Monasta, Lorenzo, Moodley, Yoshan, Moradi, Ghobad, Moradi-Lakeh, Maziar, Moradinazar, Mehdi, Moraga, Paula, Morawska, Lidia, Morgado-Da-Costa, Joana, Morrison, Shane Dougla, Moschos, Marilita M, Mouodi, Simin, Mousavi, Seyyed Meysam, Mozaffarian, Dariush, Mruts, Kalayu Brhane, Muche, Achenef Asmamaw, Muchie, Kindie Fentahun, Mueller, Ulrich Otto, Muhammed, Oumer Sada, Mukhopadhyay, Satinath, Muller, Kate, Musa, Kamarul Imran, Mustafa, Ghulam, Nabhan, Ashraf F, Naghavi, Mohsen, Naheed, Aliya, Nahvijou, Azin, Naik, Gurudatta, Naik, Nitish, Najafi, Farid, Nangia, Vinay, Nansseu, Jobert Richie, Nascimento, Bruno Ramo, Neal, Bruce, Neamati, Nahid, Negoi, Ionut, Negoi, Ruxandra Irina, Neupane, Suba, Newton, Charles Richard Jame, Ngunjiri, Josephine W, Nguyen, Anh Quynh, Nguyen, Grant, Nguyen, Ha Thu, Nguyen, Huong Lan Thi, Nguyen, Huong Thanh, Nguyen, Minh, Nguyen, Nam Ba, Nichols, Emma, Nie, Jing, Ningrum, Dina Nur Anggraini, Nirayo, Yirga Legesse, Nishi, Nobuo, Nixon, Molly R, Nojomi, Marzieh, Nomura, Shuhei, Norheim, Ole F, Noroozi, Mehdi, Norrving, Bo, Noubiap, Jean Jacque, Nouri, Hamid Reza, Nourollahpour Shiadeh, Malihe, Nowroozi, Mohammad Reza, Nsoesie, Elaine O, Nyasulu, Peter S, Obermeyer, Carla M, Odell, Christopher M, Ofori-Asenso, Richard, Ogbo, Felix Akpojene, Oh, In-Hwan, Oladimeji, Olanrewaju, Olagunju, Andrew T, Olagunju, Tinuke O, Olivares, Pedro R, Olsen, Helen Elizabeth, Olusanya, Bolajoko Olubukunola, Olusanya, Jacob Olusegun, Ong, Kanyin L, Ong, Sok King, Oren, Eyal, Orpana, Heather M, Ortiz, Alberto, Ota, Erika, Otstavnov, Stanislav S, Øverland, Simon, Owolabi, Mayowa Ojo, P A, Mahesh, Pacella, Rosana, Pakhare, Abhijit P, Pakpour, Amir H, Pana, Adrian, Panda-Jonas, Songhomitra, Park, Eun-Kee, Parry, Charles D H, Parsian, Hadi, Patel, Shanti, Pati, Sanghamitra, Patil, Snehal T, Patle, Ajay, Patton, George C, Paudel, Deepak, Paulson, Katherine R, Paz Ballesteros, Wayra Citlali, Pearce, Neil, Pereira, Alexandre, Pereira, David M, Perico, Norberto, Pesudovs, Konrad, Petzold, Max, Pham, Hai Quang, Phillips, Michael R, Pillay, Julian David, Piradov, Michael A, Pirsaheb, Meghdad, Pischon, Tobia, Pishgar, Farhad, Plana-Ripoll, Oleguer, Plass, Dietrich, Polinder, Suzanne, Polkinghorne, Kevan R, Postma, Maarten J, Poulton, Richie, Pourshams, Akram, Poustchi, Hossein, Prabhakaran, Dorairaj, Prakash, Swayam, Prasad, Narayan, Purcell, Caroline A, Purwar, Manorama B, Qorbani, Mostafa, Radfar, Amir, Rafay, Anwar, Rafiei, Alireza, Rahim, Fakher, Rahimi, Zohreh, Rahimi-Movaghar, Afarin, Rahimi-Movaghar, Vafa, Rahman, Mahfuzar, Rahman, Mohammad Hifz ur, Rahman, Muhammad Aziz, Rai, Rajesh Kumar, Rajati, Fatemeh, Rajsic, Sasa, Raju, Sree Bhushan, Ram, Usha, Ranabhat, Chhabi Lal, Ranjan, Prabhat, Rath, Goura Kishor, Rawaf, David Laith, Rawaf, Salman, Reddy, K Srinath, Rehm, Colin D, Rehm, Jürgen, Reiner, Robert C, Reitsma, Marissa B, Remuzzi, Giuseppe, Renzaho, Andre M N, Resnikoff, Serge, Reynales-Shigematsu, Luz Myriam, Rezaei, Satar, Ribeiro, Antonio Luiz P, Rivera, Juan A, Roba, Kedir Teji, Rodríguez-Ramírez, Sonia, Roever, Leonardo, Román, Yesenia, Ronfani, Luca, Roshandel, Gholamreza, Rostami, Ali, Roth, Gregory A, Rothenbacher, Dietrich, Roy, Ambuj, Rubagotti, Enrico, Rushton, Lesley, Sabanayagam, Charumathi, Sachdev, Perminder S, Saddik, Basema, Sadeghi, Ehsan, Saeedi Moghaddam, Sahar, Safari, Hosein, Safari, Yahya, Safari-Faramani, Roya, Safdarian, Mahdi, Safi, Sare, Safiri, Saeid, Sagar, Rajesh, Sahebkar, Amirhossein, Sahraian, Mohammad Ali, Sajadi, Haniye Sadat, Salam, Nasir, Salamati, Payman, Saleem, Zikria, Salimi, Yahya, Salimzadeh, Hamideh, Salomon, Joshua A, Salvi, Devashri Digvijay, Salz, Inbal, Samy, Abdallah M, Sanabria, Juan, Sanchez-Niño, Maria Dolore, Sánchez-Pimienta, Tania G, Sanders, Taren, Sang, Yingying, Santomauro, Damian Francesco, Santos, Itamar S, Santos, João Vasco, Santric Milicevic, Milena M, Sao Jose, Bruno Piassi, Sardana, Mayank, Sarker, Abdur Razzaque, Sarmiento-Suárez, Rodrigo, Sarrafzadegan, Nizal, Sartorius, Benn, Sarvi, Shahabeddin, Sathian, Brijesh, Satpathy, Maheswar, Sawant, Arundhati R, Sawhney, Monika, Saylan, Mete, Sayyah, Mehdi, Schaeffner, Elke, Schmidt, Maria Inê, Schneider, Ione J C, Schöttker, Ben, Schutte, Aletta Elisabeth, Schwebel, David C, Schwendicke, Falk, Scott, James G, Seedat, Soraya, Sekerija, Mario, Sepanlou, Sadaf G, Serre, Marc L, Serván-Mori, Edson, Seyedmousavi, Seyedmojtaba, Shabaninejad, Hosein, Shaddick, Gavin, Shafieesabet, Azadeh, Shahbazi, Mehdi, Shaheen, Amira A, Shaikh, Masood Ali, Shamah Levy, Teresa, Shams-Beyranvand, Mehran, Shamsi, Mohammadbagher, Sharafi, Heidar, Sharafi, Kiomar, Sharif, Mehdi, Sharif-Alhoseini, Mahdi, Sharifi, Hamid, Sharma, Jayendra, Sharma, Meenakshi, Sharma, Rajesh, She, Jun, Sheikh, Aziz, Shi, Peilin, Shibuya, Kenji, Shiferaw, Mekonnen Sisay, Shigematsu, Mika, Shin, Min-Jeong, Shiri, Rahman, Shirkoohi, Reza, Shiue, Ivy, Shokraneh, Farhad, Shoman, Haitham, Shrime, Mark G, Shupler, Matthew S, Si, Si, Siabani, Soraya, Sibai, Abla Mehio, Siddiqi, Tariq J, Sigfusdottir, Inga Dora, Sigurvinsdottir, Rannveig, Silva, Diego Augusto Santo, Silva, João Pedro, Silveira, Dayane Gabriele Alve, Singh, Jasvinder A, Singh, Narinder Pal, Singh, Virendra, Sinha, Dhirendra Narain, Skiadaresi, Eirini, Skirbekk, Vegard, Smith, David L, Smith, Mari, Sobaih, Badr Hasan, Sobhani, Soheila, Somayaji, Ranjani, Soofi, Moslem, Sorensen, Reed J D, Soriano, Joan B, Soyiri, Ireneous N, Spinelli, Angela, Sposato, Luciano A, Sreeramareddy, Chandrashekhar T, Srinivasan, Vinay, Starodubov, Vladimir I, Steckling, Nadine, Stein, Dan J, Stein, Murray B, Stevanovic, Goran, Stockfelt, Leo, Stokes, Mark A, Sturua, Lela, Subart, Michelle L, Sudaryanto, Agu, Sufiyan, Mu'awiyyah Babale, Sulo, Gerhard, Sunguya, Bruno F, Sur, Patrick John, Sykes, Bryan L, Szoeke, Cassandra E I, Tabarés-Seisdedos, Rafael, Tabuchi, Takahiro, Tadakamadla, Santosh Kumar, Takahashi, Ken, Tandon, Nikhil, Tassew, Segen Gebremeskel, Tavakkoli, Mohammad, Taveira, Nuno, Tehrani-Banihashemi, Arash, Tekalign, Tigist Gashaw, Tekelemedhin, Shishay Wahdey, Tekle, Merhawi Gebremedhin, Temesgen, Habtamu, Temsah, Mohamad-Hani, Temsah, Omar, Terkawi, Abdullah Sulieman, Tessema, Belay, Teweldemedhin, Mebrahtu, Thankappan, Kavumpurathu Raman, Theis, Andrew, Thirunavukkarasu, Sathish, Thomas, Hannah J, Thomas, Matthew Lloyd, Thomas, Nihal, Thurston, George D, Tilahun, Binyam, Tillmann, Taavi, To, Quyen G, Tobollik, Myriam, Tonelli, Marcello, Topor-Madry, Roman, Torre, Anna E, Tortajada-Girbés, Miguel, Touvier, Mathilde, Tovani-Palone, Marcos Roberto, Towbin, Jeffrey A, Tran, Bach Xuan, Tran, Khanh Bao, Truelsen, Thomas Clement, Truong, Nu Thi, Tsadik, Afewerki Gebremeskel, Tudor Car, Lorainne, Tuzcu, E Murat, Tymeson, Hayley D, Tyrovolas, Stefano, Ukwaja, Kingsley N, Ullah, Irfan, Updike, Rachel L, Usman, Muhammad Shariq, Uthman, Olalekan A, Vaduganathan, Muthiah, Vaezi, Afsane, Valdez, Pascual R, Van Donkelaar, Aaron, Varavikova, Elena, Varughese, Santosh, Vasankari, Tommi Juhani, Venkateswaran, Vidhya, Venketasubramanian, Narayanaswamy, Villafaina, Santo, Violante, Francesco S, Vladimirov, Sergey Konstantinovitch, Vlassov, Vasily, Vollset, Stein Emil, Vos, Theo, Vosoughi, Kia, Vu, Giang Thu, Vujcic, Isidora S, Wagnew, Fasil Shiferaw, Waheed, Yasir, Waller, Stephen G, Walson, Judd L, Wang, Yafeng, Wang, Yanping, Wang, Yuan-Pang, Weiderpass, Elisabete, Weintraub, Robert G, Weldegebreal, Fitsum, Werdecker, Andrea, Werkneh, Adhena Ayaliew, West, J Jason, Westerman, Ronny, Whiteford, Harvey A, Widecka, Justyna, Wijeratne, Tissa, Winkler, Andrea Sylvia, Wiyeh, Alison B, Wiysonge, Charles Shey, Wolfe, Charles D A, Wong, Tien Yin, Wu, Shouling, Xavier, Deni, Xu, Gelin, Yadgir, Simon, Yadollahpour, Ali, Yahyazadeh Jabbari, Seyed Hossein, Yamada, Tomohide, Yan, Lijing L, Yano, Yuichiro, Yaseri, Mehdi, Yasin, Yasin Jemal, Yeshaneh, Alex, Yimer, Ebrahim M, Yip, Paul, Yisma, Engida, Yonemoto, Naohiro, Yoon, Seok-Jun, Yotebieng, Marcel, Younis, Mustafa Z, Yousefifard, Mahmoud, Yu, Chuanhua, Zaidi, Zoubida, Zaman, Sojib Bin, Zamani, Mohammad, Zavala-Arciniega, Lui, Zhang, Anthony Lin, Zhang, Hao, Zhang, Kai, Zhou, Maigeng, Zimsen, Stephanie R M, Zodpey, Sanjay, and Murray, Christopher J L
- Subjects
Science & Technology ,GBD, risks ,risk factors ,comparative risk assesment ,Dalys ,Medicine (all) ,CHOLESTEROL ,BLOOD-PRESSURE ,11 Medical And Health Sciences ,ILLNESS ,TRENDS ,humanities ,Medicine, General & Internal ,TOBACCO CONTROL ,General & Internal Medicine ,parasitic diseases ,Medicine and Health Sciences ,CARDIOVASCULAR-DISEASES ,TRIAL ,Human medicine ,Life Sciences & Biomedicine ,METAANALYSIS - Abstract
Background The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 comparative risk assessment (CRA) is a comprehensive approach to risk factor quantification that offers a useful tool for synthesising evidence on risks and risk–outcome associations. With each annual GBD study, we update the GBD CRA to incorporate improved methods, new risks and risk–outcome pairs, and new data on risk exposure levels and risk– outcome associations. Methods We used the CRA framework developed for previous iterations of GBD to estimate levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs), by age group, sex, year, and location for 84 behavioural, environmental and occupational, and metabolic risks or groups of risks from 1990 to 2017. This study included 476 risk–outcome pairs that met the GBD study criteria for convincing or probable evidence of causation. We extracted relative risk and exposure estimates from 46 749 randomised controlled trials, cohort studies, household surveys, census data, satellite data, and other sources. We used statistical models to pool data, adjust for bias, and incorporate covariates. Using the counterfactual scenario of theoretical minimum risk exposure level (TMREL), we estimated the portion of deaths and DALYs that could be attributed to a given risk. We explored the relationship between development and risk exposure by modelling the relationship between the Socio-demographic Index (SDI) and risk-weighted exposure prevalence and estimated expected levels of exposure and risk-attributable burden by SDI. Finally, we explored temporal changes in risk-attributable DALYs by decomposing those changes into six main component drivers of change as follows: (1) population growth; (2) changes in population age structures; (3) changes in exposure to environmental and occupational risks; (4) changes in exposure to behavioural risks; (5) changes in exposure to metabolic risks; and (6) changes due to all other factors, approximated as the risk-deleted death and DALY rates, where the risk-deleted rate is the rate that would be observed had we reduced the exposure levels to the TMREL for all risk factors included in GBD 2017. Findings In 2017, 34·1 million (95% uncertainty interval [UI] 33·3–35·0) deaths and 1·21 billion (1·14–1·28) DALYs were attributable to GBD risk factors. Globally, 61·0% (59·6–62·4) of deaths and 48·3% (46·3–50·2) of DALYs were attributed to the GBD 2017 risk factors. When ranked by risk-attributable DALYs, high systolic blood pressure (SBP) was the leading risk factor, accounting for 10·4 million (9·39–11·5) deaths and 218 million (198–237) DALYs, followed by smoking (7·10 million [6·83–7·37] deaths and 182 million [173–193] DALYs), high fasting plasma glucose (6·53 million [5·23–8·23] deaths and 171 million [144–201] DALYs), high body-mass index (BMI; 4·72 million [2·99–6·70] deaths and 148 million [98·6–202] DALYs), and short gestation for birthweight (1·43 million [1·36–1·51] deaths and 139 million [131–147] DALYs). In total, risk-attributable DALYs declined by 4·9% (3·3–6·5) between 2007 and 2017. In the absence of demographic changes (ie, population growth and ageing), changes in risk exposure and risk-deleted DALYs would have led to a 23·5% decline in DALYs during that period. Conversely, in the absence of changes in risk exposure and risk-deleted DALYs, demographic changes would have led to an 18·6% increase in DALYs during that period. The ratios of observed risk exposure levels to exposure levels expected based on SDI (O/E ratios) increased globally for unsafe drinking water and household air pollution between 1990 and 2017. This result suggests that development is occurring more rapidly than are changes in the underlying risk structure in a population. Conversely, nearly universal declines in O/E ratios for smoking and alcohol use indicate that, for a given SDI, exposure to these risks is declining. In 2017, the leading Level 4 risk factor for age-standardised DALY rates was high SBP in four super-regions: central Europe, eastern Europe, and central Asia; north Africa and Middle East; south Asia; and southeast Asia, east Asia, and Oceania. The leading risk factor in the high-income super-region was smoking, in Latin America and Caribbean was high BMI, and in sub-Saharan Africa was unsafe sex. O/E ratios for unsafe sex in sub-Saharan Africa were notably high, and those for alcohol use in north Africa and the Middle East were notably low. Lancet 2018; 392: 1923–94 *Collaborators listed at the end of the paper Correspondence to: Prof Christopher J L Murray, Institute for Health Metrics and Evalution, Seattle, WA 98121, USA cjlm@uw.edu Global Health Metrics 1924 www.thelancet.com Vol 392 November 10, 2018 Interpretation By quantifying levels and trends in exposures to risk factors and the resulting disease burden, this assessment offers insight into where past policy and programme efforts might have been successful and highlights current priorities for public health action. Decreases in behavioural, environmental, and occupational risks have largely offset the effects of population growth and ageing, in relation to trends in absolute burden. Conversely, the combination of increasing metabolic risks and population ageing will probably continue to drive the increasing trends in non-communicable diseases at the global level, which presents both a public health challenge and opportunity. We see considerable spatiotemporal heterogeneity in levels of risk exposure and risk-attributable burden. Although levels of development underlie some of this heterogeneity, O/E ratios show risks for which countries are overperforming or underperforming relative to their level of development. As such, these ratios provide a benchmarking tool to help to focus local decision making. Our findings reinforce the importance of both risk exposure monitoring and epidemiological research to assess causal connections between risks and health outcomes, and they highlight the usefulness of the GBD study in synthesising data to draw comprehensive and robust conclusions that help to inform good policy and strategic health planning.
- Published
- 2018
29. Surgical resection with and without chemotherapy in oesophageal cancer.
- Author
-
Bosset J, Mercier M, Triboulet J, Conroy T, Seitz J, Chander S, Rath GK, Sharma DN, Shukla NK, Maraveyas A, O'Boyle C, Cowen M, Bancewicz J, Clark P, Girling D, Stenning S, and Weeden S
- Published
- 2002
- Full Text
- View/download PDF
30. Population-based cancer screening programmes in low-income and middle-income countries: regional consultation of the International Cancer Screening Network in India.
- Author
-
Sivaram, Sudha, Majumdar, Gautam, Perin, Douglas, Nessa, Ashrafun, Broeders, Mireille, Lynge, Elsebeth, Saraiya, Mona, Segnan, Nereo, Sankaranarayanan, Rengaswamy, Rajaraman, Preetha, Trimble, Edward, Taplin, Stephen, Rath, GK, Mehrotra, Ravi, and Rath, G K
- Subjects
- *
MEDICAL screening , *CANCER diagnosis , *DIAGNOSTIC services , *EARLY detection of cancer , *MEDICAL care , *INCOME , *INTERNATIONAL relations , *MEDICAL referrals , *NEEDS assessment , *POVERTY , *PUBLIC health surveillance , *RESEARCH funding , *TUMORS , *HUMAN services programs , *EVALUATION of human services programs ,TUMOR prevention - Abstract
The reductions in cancer morbidity and mortality afforded by population-based cancer screening programmes have led many low-income and middle-income countries to consider the implementation of national screening programmes in the public sector. Screening at the population level, when planned and organised, can greatly benefit the population, whilst disorganised screening can increase costs and reduce benefits. The International Cancer Screening Network (ICSN) was created to share lessons, experience, and evidence regarding cancer screening in countries with organised screening programmes. Organised screening programmes provide screening to an identifiable target population and use multidisciplinary delivery teams, coordinated clinical oversight committees, and regular review by a multidisciplinary evaluation board to maximise benefit to the target population. In this Series paper, we report outcomes of the first regional consultation of the ICSN held in Agartala, India (Sept 5-7, 2016), which included discussions from cancer screening programmes from Denmark, the Netherlands, USA, and Bangladesh. We outline six essential elements of population-based cancer screening programmes, and share recommendations from the meeting that policy makers might want to consider before implementation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
31. Radiation-induced malignant gliomas: is there a role for reirradiation? In regard to Paulino et Al. (Int j radiat oncol biol phys epub 2008 feb 8)
- Author
-
Bahl A, Sharma DN, Kumar M, Basu KS, and Rath GK
- Published
- 2008
- Full Text
- View/download PDF
32. Does image-guided radiotherapy (IG-IMRT) improve toxicity profile in whole pelvic-treated high-risk prostate cancer? Comparison between IG-IMRT and IMRT: In regard to Chung et al. (Int J Radiat Oncol Biol Phys 2008. In press).
- Author
-
Jothybasu KS, Bahl A, Subramani V, Sharma DN, Rath GK, Jothybasu, K S, Bahl, Amit, Subramani, Velliyan, Sharma, Daya N, and Rath, Gaura K
- Published
- 2008
- Full Text
- View/download PDF
33. Management of Extraocular Retinoblastoma: ICMR Consensus Guidelines.
- Author
-
Madan R, Radhakrishnan V, Meel R, Chinnaswamy G, Singh L, Kulkarni S, Sasi A, Kaur T, Sharma J, Dhaliwal RS, Haldorai M, Rath GK, and Bakhshi S
- Subjects
- Humans, Combined Modality Therapy standards, Consensus, Retinal Neoplasms therapy, Retinal Neoplasms diagnosis, Retinoblastoma therapy, Retinoblastoma diagnosis
- Abstract
Retinoblastoma (RB) is the most common intraocular malignancy of childhood. Advanced stage presentation of RB is common in low middle-income countries (LMICs) due to lack of awareness, social taboos associated with enucleation, seeking alternative conservative treatment options, and poor accessibility to health care. Over the last few decades, there have been significant advancements in the management of extraocular RB (EORB) which have improved outcomes and helped in minimizing treatment-related toxicities. The incorporation of multimodality approaches including chemotherapy, surgery, and radiotherapy (RT) has shown promising results; however, prognosis remains poor especially in LMICs. In this article, authors have discussed the ICMR consensus guidelines on the management of EORB, including metastatic RB., (© 2024. The Author(s), under exclusive licence to Dr. K C Chaudhuri Foundation.)
- Published
- 2024
- Full Text
- View/download PDF
34. Molecular biomarkers involved in the progression of gallbladder inflammatory lesions to invasive cancer: A proteomic approach.
- Author
-
Rawal N, Hariprasad G, Bandyopadhyay S, Ranjan Dash N, Kumar S, Das P, Dey S, Ahmad Khan M, Ranjan A, Chopra A, Saluja S, Hussain S, Rath GK, Kaur T, and Tanwar P
- Abstract
The progression of gallbladder inflammatory lesions to invasive cancer remains poorly understood, necessitating research on biomarkers involved in this transition. This study aims to identify and validate proteins associated with this progression, offering insights into potential diagnostic biomarkers for gallbladder cancer (GBC). Label-free liquid chromatography assisted tandem mass spectrometry (LC-MS/MS) proteomics was performed on samples from 10 cases each of GBC and inflammatory lesions, with technical duplicates. Validation was conducted through the enzyme-linked immunosorbent assay (ELISA) using 80 samples (40 GBC and 40 inflammatory lesions). Bioinformatics tools analyzed protein-protein interaction (PPI) networks and pathways. Statistical correlations with clinicopathological variables were assessed. Prognostic evaluation utilized Kaplan-Meier survival analysis and Cox regression analyses. mRNA expressions were studied using real time-polymerase chain reaction (RT-PCR). Out of 5,714 proteins analyzed, 621 were differentially expressed. Three upregulated (the S100 calcium-binding protein P [S100P], polymeric immunoglobulin receptor [PIGR], and complement C1q-binding protein [C1QBP]) and two downregulated (transgelin [TAGLN] and calponin 1 [CNN1]) proteins showed significant expression. Pathway analysis implicated involvement of proteoglycans in cancer and glycosaminoglycan metabolism. Significant correlations were observed between protein concentrations and clinicopathological variables. Prognostic factors such as tumor size, lymph node metastasis, and preoperative bilirubin levels were associated with overall survival. Protein-based assays demonstrated higher resolution compared to mRNA analysis, suggesting their utility in GBC risk stratification. S100P, PIGR, C1QBP, TAGLN, and CNN1 emerge as potential protein-based biomarkers involved in the progression from gallbladder inflammatory lesions to invasive cancer. These findings hold promise for improved diagnostic and prognostic strategies in GBC management.
- Published
- 2024
- Full Text
- View/download PDF
35. Genomic landscape of gallbladder cancer: insights from whole exome sequencing.
- Author
-
Awasthi S, Kumar R, Pradhan D, Rawal N, Goel H, Sahu P, Sisodiya S, Rana R, Kumar S, Dash NR, Das P, Agrawal U, Rath GK, Kaur T, Dhaliwal RS, Hussain S, Saluja SS, and Tanwar P
- Abstract
Background: Gallbladder carcinoma (GBC) is a common gastrointestinal malignancy noted for its aggressive characteristics and poor prognosis, which is mostly caused by delayed detection. However, the scarcity of information regarding somatic mutations in Indian patients with GBC has hampered the development of efficient therapeutic options. In the present study, we attempted to bridge this gap by revealing the mutational profile of GBC., Materials and Methods: To evaluate the somatic mutation profile, whole exome sequencing (WES) was performed on 66 matched tumor and blood samples from individuals with GBC. Somatic variant calling was performed using GATK pipeline. Variants were annotated at pathogenic and oncogenic levels, using ANNOVAR, VEP tools and the OncoKB database. Mutational signature analysis, oncogenic pathway analysis and cancer driver genes identification were performed at the functional level by using the maftools package., Results: Our findings focused on the eight most altered genes with pathogenic and oncogenic mutations: TP53, SMAD4, ERBB3, KRAS, ARID1A, PIK3CA, RB1, and AXIN1. Genes with pathogenic single nucleotide variations (SNVs) were enriched in oncogenic signaling pathways, particularly RTK-RAS, WNT, and TP53 pathways. Furthermore, our research related certain mutational signatures, such as cosmic 1, cosmic 6, and cosmic 18, 29, to known characteristics including patient age and tobacco smoking, providing important insights into disease etiology., Conclusions: Given the scarcity of exome-based sequencing studies focusing on the Indian population, this study represents a significant step forward in providing a framework for additional in-depth mutational analysis. Genes with substantial oncogenic and pathogenic mutations are promising candidates for developing targeted mutation panels, particularly for GBC detection., (Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2024
- Full Text
- View/download PDF
36. Somatic mutational landscape across Indian breast cancer cases by whole exome sequencing.
- Author
-
Kumar R, Awasthi S, Pradhan D, Kumar R, Goel H, Singh J, Haider I, Deo SVS, Kumar C, Srivastava A, Bhatnagar A, Kumar R, Lakshmi S, Augustine P, Ranjan A, Chopra A, Gogia A, Batra A, Mathur S, Rath GK, Kaur T, Dhaliwal RS, Mathew A, Agrawal U, Hussain S, and Tanwar P
- Subjects
- Humans, Female, Middle Aged, Adult, India epidemiology, Biomarkers, Tumor genetics, Aged, DNA Mutational Analysis, Breast Neoplasms genetics, Exome Sequencing, Mutation
- Abstract
Breast cancer (BC) has emerged as the most common malignancy among females. The genomic profile of BC is diverse in nature and complex due to heterogeneity among various geographically different ethnic groups. The primary objective of this study was to carry out a comprehensive mutational analysis of Indian BC cases by performing whole exome sequencing. The cohort included patients with a median age of 48 years. TTN, TP53, MUC16, SYNE1, and OBSCN were the frequently altered genes found in our cohort. The PIK3CA and KLC3 genes are driver genes implicated in various cellular functions and cargo transportation through microtubules, respectively. Except for CCDC168 and PIK3CA, several gene pairings were found to be significantly linked with co-occurrence. Irrespective of their hormonal receptor status, RTK/RAS was observed with frequently altered signaling pathways. Further analysis of the mutational signature revealed that SBS13, SBS6, and SBS29 were mainly observed in our cohort. This study supplements the discovery of diagnostic biomarkers and provides new therapeutic options for the improved management of BC., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
37. The Global, Regional, and National Burden of Adult Lip, Oral, and Pharyngeal Cancer in 204 Countries and Territories: A Systematic Analysis for the Global Burden of Disease Study 2019.
- Author
-
Cunha ARD, Compton K, Xu R, Mishra R, Drangsholt MT, Antunes JLF, Kerr AR, Acheson AR, Lu D, Wallace LE, Kocarnik JM, Fu W, Dean FE, Pennini A, Henrikson HJ, Alam T, Ababneh E, Abd-Elsalam S, Abdoun M, Abidi H, Abubaker Ali H, Abu-Gharbieh E, Adane TD, Addo IY, Ahmad A, Ahmad S, Ahmed Rashid T, Akonde M, Al Hamad H, Alahdab F, Alimohamadi Y, Alipour V, Al-Maweri SA, Alsharif U, Ansari-Moghaddam A, Anwar SL, Anyasodor AE, Arabloo J, Aravkin AY, Aruleba RT, Asaad M, Ashraf T, Athari SS, Attia S, Azadnajafabad S, Azangou-Khyavy M, Badar M, Baghcheghi N, Banach M, Bardhan M, Barqawi HJ, Bashir NZ, Bashiri A, Benzian H, Bernabe E, Bhagat DS, Bhojaraja VS, Bjørge T, Bouaoud S, Braithwaite D, Briko NI, Calina D, Carreras G, Chakraborty PA, Chattu VK, Chaurasia A, Chen MX, Cho WCS, Chu DT, Chukwu IS, Chung E, Cruz-Martins N, Dadras O, Dai X, Dandona L, Dandona R, Daneshpajouhnejad P, Darvishi Cheshmeh Soltani R, Darwesh AM, Debela SA, Derbew Molla M, Dessalegn FN, Dianati-Nasab M, Digesa LE, Dixit SG, Dixit A, Djalalinia S, El Sayed I, El Tantawi M, Enyew DB, Erku DA, Ezzeddini R, Fagbamigbe AF, Falzone L, Fetensa G, Fukumoto T, Gaewkhiew P, Gallus S, Gebrehiwot M, Ghashghaee A, Gill PS, Golechha M, Goleij P, Gomez RS, Gorini G, Guimaraes ALS, Gupta B, Gupta S, Gupta VB, Gupta VK, Haj-Mirzaian A, Halboub ES, Halwani R, Hanif A, Hariyani N, Harorani M, Hasani H, Hassan AM, Hassanipour S, Hassen MB, Hay SI, Hayat K, Herrera-Serna BY, Holla R, Horita N, Hosseinzadeh M, Hussain S, Ilesanmi OS, Ilic IM, Ilic MD, Isola G, Jaiswal A, Jani CT, Javaheri T, Jayarajah U, Jayaram S, Joseph N, Kadashetti V, Kandaswamy E, Karanth SD, Karaye IM, Kauppila JH, Kaur H, Keykhaei M, Khader YS, Khajuria H, Khanali J, Khatib MN, Khayat Kashani HR, Khazeei Tabari MA, Kim MS, Kompani F, Koohestani HR, Kumar GA, Kurmi OP, La Vecchia C, Lal DK, Landires I, Lasrado S, Ledda C, Lee YH, Libra M, Lim SS, Listl S, Lopukhov PD, Mafi AR, Mahumud RA, Malik AA, Mathur MR, Maulud SQ, Meena JK, Mehrabi Nasab E, Mestrovic T, Mirfakhraie R, Misganaw A, Misra S, Mithra P, Mohammad Y, Mohammadi M, Mohammadi E, Mokdad AH, Moni MA, Moraga P, Morrison SD, Mozaffari HR, Mubarik S, Murray CJL, Nair TS, Narasimha Swamy S, Narayana AI, Nassereldine H, Natto ZS, Nayak BP, Negru SM, Nggada HA, Nouraei H, Nuñez-Samudio V, Oancea B, Olagunju AT, Omar Bali A, Padron-Monedero A, Padubidri JR, Pandey A, Pardhan S, Patel J, Pezzani R, Piracha ZZ, Rabiee N, Radhakrishnan V, Radhakrishnan RA, Rahmani AM, Rahmanian V, Rao CR, Rao SJ, Rath GK, Rawaf DL, Rawaf S, Rawassizadeh R, Razeghinia MS, Rezaei N, Rezaei N, Rezaei N, Rezapour A, Riad A, Roberts TJ, Romero-Rodríguez E, Roshandel G, S M, S N C, Saddik B, Saeb MR, Saeed U, Safaei M, Sahebazzamani M, Sahebkar A, Salek Farrokhi A, Samy AM, Santric-Milicevic MM, Sathian B, Satpathy M, Šekerija M, Senthilkumaran S, Seylani A, Shafaat O, Shahsavari HR, Shamsoddin E, Sharew MM, Sharifi-Rad J, Shetty JK, Shivakumar KM, Shobeiri P, Shorofi SA, Shrestha S, Siddappa Malleshappa SK, Singh P, Singh JA, Singh G, Sinha DN, Solomon Y, Suleman M, Suliankatchi Abdulkader R, Taheri Abkenar Y, Talaat IM, Tan KK, Tbakhi A, Thiyagarajan A, Tiyuri A, Tovani-Palone MR, Unnikrishnan B, Vo B, Volovat SR, Wang C, Westerman R, Wickramasinghe ND, Xiao H, Yu C, Yuce D, Yunusa I, Zadnik V, Zare I, Zhang ZJ, Zoladl M, Force LM, and Hugo FN
- Subjects
- Adult, Female, Humans, Male, Global Health, Incidence, Lip, Quality-Adjusted Life Years, Risk Factors, Tobacco Use epidemiology, Global Burden of Disease, Pharyngeal Neoplasms epidemiology
- Abstract
Importance: Lip, oral, and pharyngeal cancers are important contributors to cancer burden worldwide, and a comprehensive evaluation of their burden globally, regionally, and nationally is crucial for effective policy planning., Objective: To analyze the total and risk-attributable burden of lip and oral cavity cancer (LOC) and other pharyngeal cancer (OPC) for 204 countries and territories and by Socio-demographic Index (SDI) using 2019 Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study estimates., Evidence Review: The incidence, mortality, and disability-adjusted life years (DALYs) due to LOC and OPC from 1990 to 2019 were estimated using GBD 2019 methods. The GBD 2019 comparative risk assessment framework was used to estimate the proportion of deaths and DALYs for LOC and OPC attributable to smoking, tobacco, and alcohol consumption in 2019., Findings: In 2019, 370 000 (95% uncertainty interval [UI], 338 000-401 000) cases and 199 000 (95% UI, 181 000-217 000) deaths for LOC and 167 000 (95% UI, 153 000-180 000) cases and 114 000 (95% UI, 103 000-126 000) deaths for OPC were estimated to occur globally, contributing 5.5 million (95% UI, 5.0-6.0 million) and 3.2 million (95% UI, 2.9-3.6 million) DALYs, respectively. From 1990 to 2019, low-middle and low SDI regions consistently showed the highest age-standardized mortality rates due to LOC and OPC, while the high SDI strata exhibited age-standardized incidence rates decreasing for LOC and increasing for OPC. Globally in 2019, smoking had the greatest contribution to risk-attributable OPC deaths for both sexes (55.8% [95% UI, 49.2%-62.0%] of all OPC deaths in male individuals and 17.4% [95% UI, 13.8%-21.2%] of all OPC deaths in female individuals). Smoking and alcohol both contributed to substantial LOC deaths globally among male individuals (42.3% [95% UI, 35.2%-48.6%] and 40.2% [95% UI, 33.3%-46.8%] of all risk-attributable cancer deaths, respectively), while chewing tobacco contributed to the greatest attributable LOC deaths among female individuals (27.6% [95% UI, 21.5%-33.8%]), driven by high risk-attributable burden in South and Southeast Asia., Conclusions and Relevance: In this systematic analysis, disparities in LOC and OPC burden existed across the SDI spectrum, and a considerable percentage of burden was attributable to tobacco and alcohol use. These estimates can contribute to an understanding of the distribution and disparities in LOC and OPC burden globally and support cancer control planning efforts.
- Published
- 2023
- Full Text
- View/download PDF
38. Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial.
- Author
-
Mallick S, Gupta S, Amariyil A, Kunhiparambath H, Laviraj MA, Sharma S, Sagiraju HKR, Julka PK, Sharma D, and Rath GK
- Subjects
- Humans, Temozolomide therapeutic use, Disease-Free Survival, Antineoplastic Agents, Alkylating therapeutic use, Glioblastoma drug therapy, Brain Neoplasms drug therapy, Brain Neoplasms surgery
- Abstract
Background: Glioblastoma (GBM) patients have poor survival outcomes despite treatment advances and most recurrences occur within the radiation field. Survival outcomes after dose escalation through hypofractionated accelerated RT(HART) were evaluated in this study. We previously reported the study's initial results showing similar survival outcomes with acceptable toxicities. Updated results after 5 years are being analysed to determine long-term survival trends., Patients and Methods: 89 patients of newly diagnosed GBM after surgery were randomized to conventional radiotherapy (CRT) or HART. CRT arm received adjuvant RT 60 Gy in 30 fractions over 6 weeks and the HART arm received 60 Gy in 20 fractions over 4 weeks, both with concurrent and adjuvant temozolomide., Results: 83 patients were eligible for analysis. After a median follow-up of 18.9 months, the median OS was 26.5 months and 22.4 months in the HART and CRT arms respectively. 5 year OS was 18.4% in the HART arm versus 3.8% in the CRT arm. This numerical difference in overall survival between the two arms was not statistically significant. The median PFS was not significantly different., Conclusion: The long-term results of the trial support HART as a promising treatment option with comparable survival outcomes to the current standard of care. Phase III trials are required for further validation of this regimen which has the potential to become the new standard of care in GBM., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
39. Consensus guidelines for the management of HR-positive HER2/neu negative early breast cancer in India, SAARC region and other LMIC by DELPHI survey method.
- Author
-
Parikh P, Babu G, Singh R, Krishna V, Bhatt A, Bansal I, Rajappa S, Sahoo TP, Aggarwal S, Bapna A, Biswas G, Somashekhar SP, Bajpai J, Maniar V, Desai S, Raja T, and Rath GK
- Subjects
- Humans, Female, Prospective Studies, Developing Countries, Retrospective Studies, Surveys and Questionnaires, Receptor, ErbB-2 genetics, Receptor, ErbB-2 therapeutic use, Breast Neoplasms epidemiology, Breast Neoplasms genetics, Breast Neoplasms therapy, Triple Negative Breast Neoplasms
- Abstract
Background: Precise prognostication is the key to optimum and effective treatment planning for early-stage hormone receptor (HR) positive, HER2/neu negative breast cancer patients. Differences in the breast cancer incidence and tumor anatomical features at diagnosis, pharmacogenomics data between Western and Indian women along with the vast diversity in the economic status and differences in insurance policies of these regions; suggest recommendations put forward for Western women might not be applicable to Indian/Asian women. Opinions from oncologists through a voting survey on various prognostic factors/tools to be considered for planning adjuvant therapy are consolidated in this report for the benefit of oncologists of the sub-continent, SAARC and Asia's LMIC (low and middle-income countries)., Methods: A three-phase DELPHI survey was conducted to collect opinions on prognostic factors considered for planning adjuvant therapy in early-stage HR+/HER2/neu negative breast cancer patients. A panel of 25 oncologists with expertise in breast cancer participated in the survey conducted in 2021. The experts provided opinions as 'agree' or disagree' or 'not sure' in phases-1 and 2 which were conducted virtually; in the final phase-3, all the panel experts met in person and concluded the survey., Results: Opinions on 41 statements related to prognostic factors/tools and their implications in planning adjuvant endocrine/chemotherapy were collected. All the statements were supported by the latest data from the clinical trials (prospective/retrospective). The statements with opinions of consensus less than 66% were disseminated in phase-2, and later in phase-3 with supporting literature. In phase-3, all the opinions from panelists were consolidated and guidelines were framed., Conclusions: This consensus guideline will assist oncologists of India, SAARC and LMIC countries in informed clinical decision-making on adjuvant treatment in early HR+/HER2/neu negative breast cancer patients., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
40. Translational cancer research in India: Challenges and Promises.
- Author
-
Gandhi AK, Rastogi M, and Rath GK
- Subjects
- Humans, Proteomics, India epidemiology, Translational Research, Biomedical, Neoplasms epidemiology, Neoplasms therapy
- Abstract
Competing Interests: None
- Published
- 2023
- Full Text
- View/download PDF
41. The issues and challenges with cancer biomarkers.
- Author
-
Purkayastha K, Dhar R, Pethusamy K, Srivastava T, Shankar A, Rath GK, and Karmakar S
- Subjects
- Child, Humans, Biomarkers metabolism, Cost-Effectiveness Analysis, Biomarkers, Tumor metabolism, Neoplasms diagnosis
- Abstract
A biomarker is a measurable indicator used to distinguish precisely/objectively either normal biological state/pathological condition/response to a specific therapeutic intervention. The use of novel molecular biomarkers within evidence-based medicine may improve the diagnosis/treatment of disease, improve health outcomes, and reduce the disease's socio-economic impact. Presently cancer biomarkers are the backbone of therapy, with greater efficacy and better survival rates. Cancer biomarkers are extensively used to treat cancer and monitor the disease's progress, drug response, relapses, and drug resistance. The highest percent of all biomarkers explored are in the domain of cancer. Extensive research using various methods/tissues is carried out for identifying biomarkers for early detection, which has been mostly unsuccessful. The quantitative/qualitative detection of various biomarkers in different tissues should ideally be done in accordance with qualification rules laid down by the Early Detection Research Network (EDRN), Program for the Assessment of Clinical Cancer Tests (PACCT), and National Academy of Clinical Biochemistry. Many biomarkers are presently under investigation, but lacunae lie in the biomarker's sensitivity and specificity. An ideal biomarker should be quantifiable, reliable, of considerable high/low expression, correlate with the outcome progression, cost-effective, and consistent across gender and ethnic groups. Further, we also highlight that these biomarkers' application remains questionable in childhood malignancies due to the lack of reference values in the pediatric population. The development of a cancer biomarker stands very challenging due to its complexity and sensitivity/resistance to the therapy. In past decades, the cross-talks between molecular pathways have been targeted to study the nature of cancer. To generate sensitive and specific biomarkers representing the pathogenesis of specific cancer, predicting the treatment responses and outcomes would necessitate inclusion of multiple biomarkers., Competing Interests: None
- Published
- 2023
- Full Text
- View/download PDF
42. Advances in Radiation Oncology: Current Status and Future Directions in India.
- Author
-
Rath GK and Kumar Gandhi A
- Abstract
Radiation therapy is one of the core components of the comprehensive cancer care. Several new advancements in the radiation physics, radiation biology, and technical upgradation have led us in to a new era of radiation oncology. The access to quality radiation therapy treatment however remains a concern, and this mini-review emphasizes on these issues and also focuses on the future directions for radiation oncology in India., Competing Interests: Conflict of InterestThe authors declare no competing interests., (© The Author(s), under exclusive licence to Indian Association of Surgical Oncology 2022.)
- Published
- 2022
- Full Text
- View/download PDF
43. Systematic Review and Individual Patient Data Analysis of Uncommon Variants of Glioblastoma: An Analysis of 196 Cases.
- Author
-
Mallick S, Benson R, Venkatesulu B, Melgandi W, and Rath GK
- Subjects
- Humans, Male, Female, Temozolomide therapeutic use, Data Analysis, Retrospective Studies, Antineoplastic Agents, Alkylating therapeutic use, Glioblastoma, Brain Neoplasms surgery, Neuroectodermal Tumors, Primitive drug therapy
- Abstract
Objectives: Different variant of GBM has been reported viz. Epithelioid Glioblastoma (GBM-E), Rhabdoid GBM (GBM-R), Small cell GBM (GBM-SC), Giant cell GBM (GBM-GC), GBM with neuro ectodermal differentiation (GBM-PNET) with unknown behavior., Materials: We conducted a systematic review and individual patient data analysis of these rare GBM variants. We searched PubMed, google search, and Cochrane library for eligible studies till July 1
st 2016 published in English language and collected data regarding age, sex, subtype and treatment received, Progression Free Survival (PFS), Overall Survival (OS). Statistical Package for social sciences (SPSS) v16 software was used for all statistical analysis., Results: We retrieved data of 196 patients with rare GBM subtypes. Among these GBM-GC is commonest (51%), followed by GBM-R (19%), GBM-PNET (13%), GBM-SC (9%) and GBM-E (8%). Median age at diagnosis was 38, 40, 43.5, 69.5 and 18 years, respectively. Male: female ratio was 2:1 for GBM-E, and 1:3 for GBM-SC. Maximal safe resection followed by adjuvant local radiation was used for most of the patients. However, 6 patients with GBM-PNET, 3 each of GBM-E, GBM-SC received adjuvant craniospinal radiation. Out of 88 patients who received chemotherapy, 64 received Temozolomide alone or combination chemotherapy containing Temozolomide. Median PFS and OS for the entire cohort were 9 and 16 months. In univariate analysis, patient with a Gross Total Resection had significantly better PFS and OS compared to those with a Sub Total Resection [23 vs. 13 months (p-0.01)]. Median OS for GBM PNET, GBM-GC, GBM-SC, GBM-R and GBM-E were 32, 18.3, 11, 12 and 7.7 months, respectively (P = 0.001). Interestingly, 31.3%, 37.8% of patients with GBM-E, GBM-R had CSF dissemination., Conclusion: Overall cohort of rarer GBM variant has equivalent survival compared to GBM not otherwise specified. However, epithelioid and Rhabdoid GBM has worst survival and one third shows CSF dissemination., Competing Interests: None- Published
- 2022
- Full Text
- View/download PDF
44. Consensus guidelines on management of oral potentially malignant disorders.
- Author
-
Birur PN, Patrick S, Warnakulasuriya S, Gurushanth K, Raghavan SA, Rath GK, Chaturvedi P, Chandru V, Mathew B, Prabhash K, Gurudath S, Mukhia N, Sunny SP, Mehrotra R, Vivek V, Patil S, Kumar GS, Fasalkar S, Pratima R, and Kuriakose MA
- Subjects
- Humans, Squamous Cell Carcinoma of Head and Neck, Mouth Neoplasms diagnosis, Mouth Neoplasms therapy, Mouth Neoplasms pathology, Carcinoma, Squamous Cell diagnosis, Carcinoma, Squamous Cell therapy, Carcinoma, Squamous Cell pathology, Precancerous Conditions diagnosis, Precancerous Conditions therapy, Mouth Diseases pathology, Head and Neck Neoplasms
- Abstract
Oral cancer is usually preceded by oral potentially malignant disorders (OPMDs) and early detection can downstage the disease. The majority of OPMDs are asymptomatic in early stages and can be detected on routine oral examination. Though only a proportion of OPMDs may transform to oral squamous cell carcinoma (OSCC), they may serve as a surrogate clinical lesion to identify individuals at risk of developing OSCC. Currently, there is a scarcity of scientific evidence on specific interventions and management of OPMDs and there is no consensus regarding their management. A consensus meeting with a panel of experts was convened to frame guidelines for clinical practices and recommendations for management strategies for OPMDs. A review of literature from medical databases was conducted to provide the best possible evidence and provide recommendations in management of OPMDs., Competing Interests: None
- Published
- 2022
- Full Text
- View/download PDF
45. Leveraging epigenetics to enhance the efficacy of cancer-testis antigen: a potential candidate for immunotherapy.
- Author
-
Gupta R, Jit BP, Kumar S, Mittan S, Tanwer P, Ray MD, Mathur S, Perumal V, Kumar L, Rath GK, and Sharma A
- Subjects
- Antigens, Neoplasm genetics, Antigens, Neoplasm metabolism, Carcinoma, Ovarian Epithelial genetics, Epigenesis, Genetic, Female, Humans, Immunotherapy, Male, Membrane Proteins genetics, Ovarian Neoplasms genetics, Ovarian Neoplasms therapy, Testis
- Abstract
Ovarian cancer is the most lethal gynecological malignancy in women. The phenotype is characterized by delayed diagnosis, recurrence and drug resistance. Inherent immunogenicity potential, oncogenic function and expression of cancer-testis/germline antigen (CTA) in ovarian cancer render them a potential candidate for immunotherapy. Revolutionary clinical findings indicate that tumor antigen-mediated T-cell and dendritic cell-based immunotherapeutic approaches provide an excellent strategy for targeting tumors. Currently, dendritic cell vaccination for the treatment of B-cell lymphoma and CTA-based T-cell receptor transduced T-cell therapy involving MAGE-A4 and NY-ESO-1 are well documented and shown to be effective. This review highlighted the mechanical aspects of epigenetic drugs that can elicit a CTA-based humoral and cellular immune response and implicate T-cell and dendritic cell-based immunotherapeutic approaches.
- Published
- 2022
- Full Text
- View/download PDF
46. Demography, patterns of care, and survival outcomes in patients with salivary duct carcinoma: an individual patient data analysis of 857 patients.
- Author
-
Giridhar P, Venkatesulu BP, Yoo R, V P, Rath GK, Mallick S, Upadhyay A, and Chan DP
- Abstract
Aim: Salivary duct carcinoma (SDC) is a rare and aggressive malignancy. The optimal treatment protocols are debated., Methodology: A systematic search and individual patient data analysis of published cases of SDC was performed. SPSS v21 was used for statistical analysis., Results: Data of 857 patients available. Median overall survival (OS) and progression-free survival (PFS) of the entire cohort 42 months and 24 months. Nodal involvement, males, primary size >5 cm, androgen receptor (AR) negativity significantly worse OS. Patients with surgery had a favorable median PFS (p = 0.000) and OS (p = 0.077). Patients with adjuvant radiation had better PFS (30 vs 18 months; p = 0.077)., Conclusion: SDC has modest survival. Surgery and adjuvant radiation should be advocated for all patients. AR expression appears prognostic for survival., Competing Interests: Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript., (© 2022 Bhanu Prasad Venkatesulu.)
- Published
- 2022
- Full Text
- View/download PDF
47. Rosette Forming Glioneural Tumor Treated with Conformal Radiation.
- Author
-
Giridhar P, Mallick S, Haresh KP, Gupta S, and Rath GK
- Subjects
- Fourth Ventricle pathology, Humans, Brain Neoplasms pathology, Brain Neoplasms radiotherapy, Cerebral Ventricle Neoplasms pathology, Cerebral Ventricle Neoplasms radiotherapy, Neoplasms, Neuroepithelial pathology, Neoplasms, Neuroepithelial radiotherapy, Radiotherapy, Conformal
- Abstract
Rosette forming glioneural tumors (RGNT) are a rare type of low-grade brain tumor included in 2007 in WHO classification. Given the benign nature of the disease, a complete surgical excision has been considered optimum. However, a handful of cases have reported the locally aggressive nature of RGNT. In addition, radiation may also be considered for a tumor located in areas where surgical excision is difficult. We present a similar case, where surgical risk was weighed against resection and we treated the patient with conformal radiation., Competing Interests: None
- Published
- 2022
- Full Text
- View/download PDF
48. Practical Consensus Recommendations for Optimizing Risk versus Benefit of Chemotherapy in Patients with HR Positive Her2 Negative Early Breast Cancer in India.
- Author
-
Parikh PM, Bhattacharyya GS, Biswas G, Krishnamurty A, Doval D, Heroor A, Sharma S, Deshpande R, Chaturvedi H, Somashekhar SP, Babu G, Reddy GK, Sarkar D, Desai C, Malhotra H, Rohagi N, Bapna A, Alurkar SS, Krishna P, Deo SVS, Shrivastava A, Chitalkar P, Majumdar SK, Vijay D, Thoke A, Udupa KS, Bajpai J, Rath GK, Dattatreya PS, Bondarde S, and Patil S
- Abstract
Breast cancer is a public health challenge globally as well as in India. Improving outcome and cure requires appropriate biomarker testing to assign risk and plan treatment. Because it is documented that significant ethnic and geographical variations in biological and genetic features exist worldwide, such biomarkers need to be validated and approved by authorities in the region where these are intended to be used. The use of western guidelines, appropriate for the Caucasian population, can lead to inappropriate overtreatment or undertreatment in Asia and India. A virtual meeting of domain experts discussed the published literature, real-world practical experience, and results of opinion poll involving 185 oncologists treating breast cancer across 58 cities of India. They arrived at a practical consensus recommendation statement to guide community oncologists in the management of hormone positive (HR-positive) Her2-negative early breast cancer (EBC). India has a majority (about 50%) of breast cancer patients who are diagnosed in the premenopausal stage (less than 50 years of age). The only currently available predictive test for HR-positive Her2-negative EBC that has been validated in Indian patients is CanAssist Breast. If this test gives a score indicative of low risk (< 15.5), adjuvant chemotherapy will not increase the chance of metastasis-free survival and should not be given. This is applicable even during the ongoing COVID-19 pandemic., Competing Interests: Conflict of Interest None declared., (MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)
- Published
- 2021
- Full Text
- View/download PDF
49. Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia.
- Author
-
Goel H, Rahul E, Gupta I, Chopra A, Ranjan A, Gupta AK, Meena JP, Viswanathan GK, Bakhshi S, Misra A, Hussain S, Kumar R, Singh A, Rath GK, Sharma A, Mittan S, and Tanwar P
- Abstract
Acute myeloid leukemia (AML) is a complex, aggressive myeloid neoplasm characterized by frequent somatic mutations that influence different functional categories' genes, resulting in maturational arrest and clonal expansion. AML can arise de novo (dn-AML) or can be secondary AML (s-AML) refers to a leukemic process which may arise from an antecedent hematologic disorder (AHD-AML), mostly from a myelodysplastic syndrome (MDS) or myeloproliferative neoplasm (MPN) or can be the result of an antecedent cytotoxic chemotherapy or radiation therapy (therapy-related AML, t-AML). Clinical and biological features in secondary and therapy-related AML are distinct from de novo AML. Secondary and therapy-related AML occurs mainly in the elderly population and responds worse to therapy with higher relapse rates due to resistance to cytotoxic chemotherapy. Over the last decade, advances in molecular genetics have disclosed the sub-clonal architecture of secondary and therapy-related AML. Recent investigations have revealed that cytogenetic abnormalities and underlying genetic aberrations (mutations) are likely to be significant factors dictating prognosis and critical impacts on treatment outcome. Secondary and therapy-related AML have a poorer outcome with adverse cytogenetic abnormalities and higher recurrences of unfavorable mutations compared to de novo AML. In this review, we present an overview of the clinical features of secondary and therapy-related AML and address the function of genetic mutations implicated in the pathogenesis of secondary leukemia. Detailed knowledge of the pathogenetic mechanisms gives an overview of new prognostic markers, including targetable mutations that will presumably lead to the designing and developing novel molecular targeted therapies for secondary and therapy-related AML. Despite significant advances in knowing the genetic aspect of secondary and therapy-related AML, its influence on the disease's pathophysiology, standard treatment prospects have not significantly evolved during the past three decades. Thus, we conclude this review by summarizing the modern and developing treatment strategies in secondary and therapy-related acute myeloid leukemia., Competing Interests: None., (AJBR Copyright © 2021.)
- Published
- 2021
50. Glioblastoma with Primitive Neuroectodermal Component Treated with Adjuvant Radiotherapy and Temozolomide: A Pooled Analysis of 23 Patients.
- Author
-
Benson R, Mallick S, Purkait S, Haresh KP, Gupta S, Sharma MC, Suri V, Sharma D, and Rath GK
- Subjects
- Humans, Neoplasm Recurrence, Local, Radiotherapy, Adjuvant, Retrospective Studies, Temozolomide therapeutic use, Brain Neoplasms drug therapy, Brain Neoplasms radiotherapy, Glioblastoma drug therapy, Glioblastoma radiotherapy, Neuroectodermal Tumors, Primitive drug therapy, Neuroectodermal Tumors, Primitive radiotherapy
- Abstract
Aim: Glioblastoma (GBM) is one of the most aggressive neoplasms of the central nervous system with dismal survival. In recent years, different variants of GBM have been described in the literature. GBM with areas of neuroectodermal differentiation (GBM-PNET) is a relatively new entity in GBM. Presence of the neuroectodermal component increases the propensity of systemic dissemination as with other intracranial primitive neuroectodermal tumors (PNET). The optimal treatment for these patients remains a controversy, with authors reporting local radiotherapy to craniospinal irradiation and chemotherapy. We intend to analyze the pattern of care for GBM with neuroectodermal component., Materials and Methods: We retrieved data of four patients with GBM-PNET treated in our institute; data were also retrieved from published series to derive treatment and outcome results., Results: In this series, we report the outcome of a series of four patients of GBM-PNET treated with adjuvant radiotherapy and temozolomide. All but one patient underwent gross total resection of the tumor. Adjuvant hypofractionated radiation with concurrent and adjuvant temozolomide was used in all cases. The median follow-up was 12.9 months in the present series. One patient experienced local recurrence 18 months after the treatment. A review of published literature on GBM-PNET was done; studies with details of patient outcome were used for an independent analysis. Twenty-three patients were identified, and the pooled analysis revealed a median progression free and overall survival of 10 and 25, months respectively. Extent of surgery, local radiation vs. craniospinal irradiation, and age at presentation had no impact on the survival., Conclusion: GBM PNET is a new entity with only few cases reported so far. Clinical behavior and treatment outcome of these tumors are not different from conventional GBM. However, these patients are at higher risk of CSF dissemination. Hence, an individualized treatment approach is best suited., Competing Interests: None
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.